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1 Introduction  
1.1 Cancer 
Cancer is a group of genetic disease characterized by dynamic changes in the genetic material 
which transform the normal cells to the malignant phenotype. These changes include, gain of 
function in case of growth promoting genes, loss of function for tumor suppressor genes and 
stability genes.  
There are six characteristic changes that transform a normal human cell into a malignant cell: 
unlimited replication potential, continued angiogenesis, prevention of cell apoptosis, self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals and metastasis [1]. 
Recently, evasion of immune destruction and reprogramming of energy metabolism 
characteristics have been added to the malignant hall marks [2].   
Cancer is one of the most prevalent diseases. It is the first leading cause of death in 
economically developed countries and the second leading cause of death in the developing 
countries. In 2008 about 12.7 million cancer cases and 7.6 million cancer deaths were 
estimated worldwide. Breast cancer is the most common diagnosed cancer in females which 
account for 23% of the total cancer cases and the first leading reason with 14% of females 
cancer death worldwide, while prostate cancer and lung cancer are the leading cause of males 
cancer death in economically developed and developing countries respectively (Figure 1) [3].  
 
1.2 Cancer treatment  
Conventional treatment for solid tumors is removing the malignant tissues by surgery 
followed by chemotherapy and/or radiotherapy. Although the effectiveness of these therapies 
is good, the side effects are very high because they lack specificity to target malignant cells. 
Another obstacle with these treatments is that cancer cells develop resistance to these 
treatments.  
Chemotherapy has been the major strategy for the systemic therapy of advanced or metastatic 
cancers in the last 60 years. Chemotherapeutic agents are able to kill proliferating cells, hence 
affecting malignant cells. Despite the high efficiency of chemotherapeutic agents in inhibiting 
cancers progression their toxicity to normal tissues, particularly the rapid growing cells 
including, bone marrow, blood and mucous membrane cells, lead to significant side-effects 
[4]. Another challenge faced by chemotherapy is the inherited or acquired resistance of cancer 
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cells up a treatment using increased doses, Moreover, increased doses lead to more side-
effects [5].  
In the radiotherapy, the ionizing radiation reacts with cell biological material, including 
proteins, lipids and nucleic acids. Radiation energy is enough to break chemical bounds 
between molecules. The major damage occurs to DNA which produces a series of DNA 
double stranded breaks (DSBs).  
 
 
 
Figure 1: Estimation of new cancer cases and deaths worldwide [3]. 
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Unrepaired DNA double strand breaks can lead to chromosomal abnormality,  loss of genetic 
material and cell death [6]. This therapy also lacks specificity and can affect both normal and 
cancer cells.  
Currently, there is an obvious increase in using photodynamic therapy as an alternative cancer 
treatment. In this context several photosensitizer have been approved for use in humans in 
USA, Canada and European Union. In USA, Porfimer sodium (Photofrin) is used against 
endobronchial tumors, obstructing esophageal and invasive endobronchial non-small cell 
carcinoma. In European Union, head and neck cancers are treated using meta-
tetrahydroxyphenylchlorin (Foscan) while 5-aminolevulinic acid (Metvix ) is used to treat  
non-melanoma skin cancers [7].  
 
1.2.1 Photodynamic therapy  
Photodynamic therapy (PDT) is a promising and minimally-invasive approach for the 
treatment of cancer. Following the introduction of improved photosensitizers and clinical 
application protocols, several FDA-approved PDT drugs have become available and others 
are in various stages of preclinical and clinical development (Table 2) [8, 9].  
 
Table 2: Photosensitizers in clinical use[8].  
Platform  Drug Substance Manufacture  
Porphyrin  Photofrin® HpD Axcan Pharma Inc. 
Porphyrin  
 
Photogem® HpD Moscow Research 
Oncological Institute 
Porphyrin  Levulan® ALA DUSA 
Pharmaceuticals, Inc. 
Porphyrin  Metvix® M-ALA PhotoCure ASA 
Porphyrin Hexvix®  H-ALA PhotoCure ASA 
Porphyrin  
 
Visudyne® Verteporfin Novartis 
Pharmaceuticals 
Texaphyrin  Antrin®, Lu-Tex Lutexaphyrin Pharmacylics 
Chlorine  Foscan® Temoporfin Biolitec Pharma Ltd 
Chlorine  LS11, Photolon®, LitxTM, 
ApoptosinTM, Laserphyrin 
Talaporfin Light Sciences 
Chlorine  Photochlor HPPH RPCI 
Phthalocianines  
 
Photosens® Phthalocyanine General Physics Institute 
Phthalocianines Pc4  Phthalocyanine CWRU 
Padoporfin  
 
Tookad Bacteriochlorophyll The Weisman 
Institute of Science 
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The photosensitizing agent can exert its effect when it is directly activated by non-hazardous 
light resulting in cytotoxicity or indirectly by initiating the in situ production of toxic free 
radicals or reactive oxygen species (ROS). The site of cellular damage depends on the 
photosensitizer type, the incubation period and the mode of delivery [10]. In general, anionic 
photosensitizer localize in lysosomes, whereas cationic photosensitizers accumulate in 
mitochondria and cause damage there [11].  
When photosensitizer is activated with suitable light wavelength and dose, the energy-
enriched photosensitizer releases the extra energy to the neighboring substrates and returns 
back to its ground state. A portion of the excited singlet state molecules is converted through 
intersystem crossing into the relatively long-lived (micro-to milliseconds) excited triplet state, 
which can either generate free radicals or radical ions via hydrogen atom removal or electron 
transmission to the surrounding biological substrates, solvent molecules or oxygen [12]. 
After photosensitizer activation two types of reaction can take place. In a type I reaction, 
created radicals react with oxygen molecules to generate reactive oxygen species (ROS), 
including hydrogen peroxides, superoxide anion radicals and hydroxyl radicals. In a type II 
reaction, the energy can be transformed directly to the oxygen molecules to generate singlet 
oxygen (1O2) (Figure 3) [13].  
 
 
Figure 2: Type I and type II reactions in photodynamic therapy (PDT) [14]  
 
Photodynamic therapy can destroy cancer cells via three major mechanisms including direct 
destruction of the cells via the ROS, which is created after photosensitizer activation, by 
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inducing cell necrosis and apoptosis. Also the PDT can lead to serious damages in the tumor-
associated vasculature, in this mechanism the PDT causes microvascular collapse which 
causes a severe hypoxia and anoxia. Moreover, PDT can stimulate immune responses against 
cancer cells including expression of heat-shock proteins, acute inflammation and infiltration 
of cancer cells by leukocytes (Figure 4) [12, 13, 15-17].  
One of the greatest challenges in PDT is the lack of specificity. Photosensitizers damage 
healthy tissue as well as tumor tissue after activation by light, and also can result in prolonged 
skin photosensitivity. To increase the specificity of PDT, photosensitizers have been 
conjugated to different cell ligands including peptides [18], aptamers [19], monoclonal 
antibodies and their fragments [13, 20, 21].  
 
 
Figure 3: The photodynamic action on treated tumor cells [16].   
 
1.2.2 Nanocarrier-based chemotherapy  
Nanoparticles are a powerful imaging and therapeutic agent carriers that can increase efficacy 
and safety of conventional free drugs by overcoming their limitations, such as low capacity, 
poor drug solubility, limited stability and rapid clearance. Furthermore, multiple therapeutic 
and imaging agents can be linked to nanoparticles [22]. 
Several types of nanoparticles such as metal-, polymer- and lipid-based nanoparticles have 
been developed to deliver therapeutic agents, including chemotherapeutic agents, 
radionuclides, photosensitizers, and siRNA to target cells [23, 24].  
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1.2.3 RNA interference-based therapy   
Since the first description of RNAi process by Fire et al., significant progress has been made 
in understanding the RNAi process and in selecting siRNA against wide range of target genes. 
The siRNA have several therapeutic properties over conventional drugs. RNAi is an 
endogenous natural process generally used by cells to selectively down-regulate gene 
expression. Furthermore, selection of siRNA against specific disease is easier, safer and more 
specific than the identification of new chemical therapeutic agents [25]. 
To induce the sequence-specific cleavage of mRNA, two approaches have been used: short 
hairpin RNA (shRNA) and siRNA. While shRNA needs to be processed by a Dicer enzyme to 
generate siRNA and can be delivered to cells using both viral and non-viral methods, siRNA 
can be directly incorporated into RISC and guide the mRNA degradation (Figure 5). 
As cancer and viral infections are associated with up-regulation of certain genes, siRNA 
emerged as a very promising therapeutic agent to target and suppress specific genes in target 
cells. Though remarkable progress has been made to select siRNA against target genes, 
siRNA delivery is still one of the major challenges in the development of siRNA-based 
therapy. Several approaches have been developed to overcome this obstacle [26-29]. Using 
aptamers to deliver siRNA to specific target cells is one of the recent promising approaches 
[30-34].  
 
Figure 4: RNA interference mechanism.  
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1.3 Tumor targeted drug delivery  
Tumor targeting therapy has emerged as a strategy to overcome the lack of specificity of 
traditional therapeutic agents. Several classes of ligands have been used to deliver therapeutic 
agents to the target cells including folic acid, transferrin, peptides, hormones, vitamins, 
monoclonal antibodies, and aptamers. These ligand-therapeutic agent conjugates can reduce 
unspecific toxicity of the drug. Different factors affect the therapeutic properties of the ligand-
therapeutic agents including ligand specificity and binding affinity, conjugation strategy, 
therapeutic agent potency, linker properties and the stoichiometry of conjugated ligand-drug 
molecules [35-37]. 
Two approaches are followed for ligand mediated therapeutic agent delivery. In the first 
approach the therapeutic agent molecules are conjugated directly to the ligand [38] and in the 
second approach the ligand is conjugated to the nanoparticle which is loaded with the 
therapeutic agents [39].  
 
1.4 Antibody drug conjugation  
Traditional protein conjugation methods that have been used to conjugate therapeutic agents 
to antibodies and their fragments are: using carbodiimide that couples the therapeutic agent 
carboxyl group to the antibody amino group; modifying the therapeutic agent with N-
hydroxysuccinimide esters which can react with the amino group in the lysine residues and 
maleimide-modified drugs which react with the thiol group of cysteine residues.  
However, these conjugation strategies are unsuitable for the conjugation of therapeutic agnets 
to antibodies because there is no reliable way to ensure that antibody-drug conjugates are 
produced in the optimal stoichiometric ratio [40, 41]. Furthermore, the chemical properties of 
the drug (e.g. hydrophobicity and the number and arrangement of charged groups) can alter 
pharmacokinetic properties and biodistribution of the antibody, and may cause non-specific 
binding and internalization behavior. Random conjugation of photosensitizers can also cause 
self-quenching of photosensitizer excited states, thus reducing photodynamic activity [42]. 
The use of self-labeling proteins such as SNAP, CLIP and Halo tags can provide a unique 
conjugation site on the antibody, allowing the production of a homogeneous conjugate 
preparation [43]. 
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1.4.1 SNAP-tag technology      
The SNAP tag protein is an engineered human DNA repair enzyme alkylguanine-DNA 
alkyltransferase (AGT) that can be used as a tag for self-labeling with modified O(6)-
benzylguanine substrate via irreversible transfer of an alkyl group to a cysteine residue [44]. 
The wild type AGT scans the DNA for alkyl adducts and removes them from the O6 position 
of guanines and the O4 position of thymine.  This reaction leads to deactivation and 
degradation of the AGT enzyme. This defense process protects the DNA and decreases the 
mutagenicity and carcinogenicity rate. Furthermore, this mechanism is responsible for tumors 
developing resistance against DNA alkylating chemotherapeutic agents [45, 46]. 
Phage display libraries of AGT have been use to select a mutated AGT that has highest 
reactivity against O(6)-benzylguanine (BG) modified molecules. Furthermore, other 
mutations were introduced to the selected mutated AGT in order to reduce its binding activity 
towards DNA and its size and to remove two non-fundamental cysteines, thus facilitating  
folding under oxidizing conditions. The resulting mutated AGT (SNAP tag) is composed of 
182 amino acids and its activity is at least 50-times higher than the wild type AGT [45-47].  
The SNAP tag technology provides an easy, fast, site specific and well-defined mechanism 
with a predictable (1:1) stoichiometry and respective flexible method for labeling proteins 
with various BG-modified molecules in living cells and in vitro. This technology has been 
used in different approaches, including protein labeling in living cells [44, 48, 49], facilitating 
plasmon resonance and protein microarray surface immobilization with SNAP tag fusion 
proteins [50-52], in vivo imaging[53] and therapeutic agent delivery [54]. 
 
1.4.2 Releasing therapeutic agent from the lysosomes 
Releasing therapeutic agent from the lysosomes into the cytosol is one of the main problems 
associated with targeted drug delivery [55, 56]. It has been found that only 0.01% of the 
injected ligand reaches the malignant tissues. Also the amount of therapeutic agent that can be 
conjugated to ligand is limited. Thus, a highly potent  therapeutic agent should be conjugated 
to the ligand in order to treat cancer [57]. Also the linker technology plays a key role in 
releasing the therapeutic agent from the ligand after internalizing the cell.  
The linker should have a long half-life, serum stability and be cleavable after entering the 
cells. For this purpose, several types of acid labile linkers have been developed which exploit 
the acidic environment of the endosomes and lysosomes [58, 59]. Furthermore disulfide-
linker that release the therapeutic agents in the cytosol with a high thiol concentration [37, 60] 
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protease-cleavable peptide linkers or adapters which are digested by endosomal proteolytic 
enzymes are commonly used [55, 56]. 
  
1.4.2.1 Protease-cleavable adapter 
The nature and composition of activated lysosomes provide several options to develop a 
cleavable peptide adapter which is selectively cleaved by lysosomal enzymes and thereby 
allows the release of therapeutic agents after internalization.  A well documented lysosome 
abundant protease cathepsin B is known to cleave a specific sequence, and thus is amenable 
for development as several cathepsin B cleavable adapters [61-63].  
Several peptide adapters have been developed to improve transferring therapeutic agent to the 
cytosol including insertion of cell penetrating peptides which are short peptides with varied 
sequence that facilitate transporting cargo molecules across membranes [62, 64], endosomal 
active elements which enhance endosomal escape [62, 65] and cytosolic cleavable peptides 
which are carring a corresponding intracellular recognition motifs, allowing the cargo 
molecules to be separated from any motif or domain used for membrane translocation 
cleavable peptides [62]. 
Alternatively, a molecular adapter containing three functional elements, which are discussed 
above, was developed and used to increase uptake and/or cytotoxic efficacy of immunotoxins. 
This adapter improves the releasing of the catalytic moiety into the cytosol of treated cells and 
successively traps the toxic moiety within the cell which ultimately leads to reduce the long 
circulation and unspecific targeting side effects [61, 66, 67]. 
 
1.5 Receptor-mediated drug delivery 
1.5.1 Epidermal growth factor receptor 
EGF receptor (or ErbB1) is a transmembrane receptor belonging to a family of tyrosine 
kinases (ErbB family). This family comprises four receptors (EGFR, ErbB2, ErbB3 and 
ErbB4) and 13 extra cellular polypeptide ligands. All ErbB family members have similar 
molecular structures; each of them comprises an extracellular ligand-binding domain, a single 
α-helix transmembrane domain and an intracellular tyrosine kinase domain (excpt Erb3) that  
is flanked by regulatory domains [68, 69]. 
ErbBs are activated by the phosphorylation of the tyrosine kinase domain that promotes 
homodimerization or heterodimerization between different receptors. Receptor dimerization is 
induced by ligand binding that lead to auto-phosphorylation [70].  EGFR is overexpressed in 
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many solid tumors [71], including pancreas cancer [72, 73], head-and-neck cancer [74], 
prostate cancer [75], breast cancer [76], ovarian cancer [77], non–small-cell lung cancer [78], 
renal cancer [79], and colon cancer [80].Such overexpression produces strong signal 
generation and stimulation of downstream signaling pathways, which lead to induction of cell 
growth, signaling cascades, cell differentiation, cell cycle progression, angiogenesis and 
blocking apoptosis[71, 81]. 
The high expression and functional activation of EGFR in several cancers are very important 
characteristics, which make it an attractive target for diagnosis and therapy and several 
approaches have been developed to target the EGFR in cancer cells [71]. These approaches 
include developing of anti-EGFR monoclonal antibodies and small-molecule EGFR inhibitors 
[70, 82, 83].   
Cetuximab is a good example of an anti-EGFR monoclonal antibody, which binds specifically 
to the extracellular domain III of EGFR when it is in the inactive configuration, thereby 
inhibiting ligand binding and receptor activation. Cetuximab has been approved by FDA for 
treatment of metastatic colorectal cancer and head and neck cancer [82]. Furthermore, small-
molecule EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib are used to treat 
non-small cell lung cancer and pancreatic cancer. These molecules bind to the catalytic 
tyrosine kinase domain of EGFR and prevent ATP binding which leads to a reduction of 
EGFR autophosphorylation [70, 83]. 
 
1.5.2 αvβ3 integrin    
Integrins are cell-surface receptors and represent a subclass of cell adhesion molecules which 
link the internal cytoskeleton with the extracellular matrix (ECM) or other cells. Integrins are 
composed of two transmembrane glycoprotein subunits, α and β, which are genetically 
unrelated. These two subunits are non-covalently connected with each other. In mammals, 
there are at least 8 β and 18 α subunits able of assembling into 24 different functional 
heterodimers [84]. The integrin family plays essential roles for controlling the cellular 
activation, cell proliferation, cell differentiation, migration and cell survival [85].  The αvβ3 
integrin is a member of the integrin family, which has been extensively studied. It is 
composed of a 105-kDa β3 subunit and a 125-kDa αv subunit and connects to a vast range of 
ECM proteins [42-43]. 
Many integrins are highly expressed in tumor cells [86-90] and αvβ3 integrin is overexpressed 
specifically in several types of tumor cells like prostate, cervical and brain tumors [33, 88, 
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91]. Several studies have proved that a number of integrins are internalized into the 
endosomal compartments and then recycled back to the plasma membrane before they get 
degraded in the endosomal compartments [92-94].     
Like other integrins, αvβ3 integrin is rapidly recycled via endocytotic processes with a 
recycling rate of 30 min [94-96]. The high expression of αvβ3 integrin in cancer cells and the 
efficient and rapid recycling via endocytotic processes are important characteristics, which 
make it a good target for therapeutic agent delivery. Numerous approaches were developed to 
investigate specific delivery of several therapeutic agents including chemotherapeutic 
molecules [97-100], radionuclides [101, 102], nanoparticle [103, 104], siRNA [105, 106] and 
therapeutic peptides and proteins [107, 108] using αvβ3 integrin ligands. 
 
1.6 Monoclonal antibodies and them fragment mediated drug delivery  
Immunoglobulins or antibodies are a group of glycoproteins which specifically recognize and 
neutralize foreign antigens and play a key role in the mammalian immune system. Antibodies 
are composed of two identical heavy (55-70kDa) and light (25kDa) chains.  Functionally, an 
antibody is constructed from two distinct fragments, two antigen binding fragments (Fabs) 
and a constant (Fc) fragments, and these fragments are linked via disulfide bridges.  
Antibody-based therapeutics have been approved for many cancer types as specific targeted 
therapy. The high specificity, affinity of the monoclonal antibody and their derivatives and the 
presence of different chemical groups on them amino acids that allow further modification 
make antibodies a very powerful tool for delivery of therapeutic agents.  
 
 
 
Figure 5: Structure of an antibody molecule composed of two heavy and two light chains linked by disulfide 
bridges [109].  
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Several mAbs have been approved for human malignancy disease treatment like chronic 
lymphocytic leukaemia, colorectal cancer, lung cancer, breast cancer, Non-Hodgkin’s 
lymphoma and acute myelogenous leukaemia (Table 1) [110].  
Although antibodies have been proposed to deliver drugs against tumors since several 
decades, only two ADCs have been approved for human treatment. The first FDA approved-
ADC was gemtuzumab ozogamicin for treating acute myeloid leukemia in 2000. However, 
this ADC was withdrawn from the market in 2010 because the phase III trials showed that 
both gemtuzumab plus chemotherapy and the chemotherapy alone had the same treatment 
effects. Moreover, the gemtuzumab ozogamicin showed significantly higher rate of fatal 
adverse results [111].      
Table 1: FDA approved mAb for cancer therapy [110]. 
Generic name Approval date Type Target Approved indications 
Alemtuzumab 2001 Humanised CD52 Chronic lymphocytic leukaemia 
Bevacizumab 2004 Humanised VEGF Colorectal cancer, lung cancer 
Cetuximab 2004 Chimeric  EGFR Colorectal cancer refractory to 
irinotecan for head/neck cancer 
with radiotherapy  
Gemtuzumab 
ozogamicin 
2005 Humanised CD33 Acute myelogenous leukaemia 
(with calicheamicin) 
Ibritumomab 
tiuxetan 
2002 Murine CD20 Non-Hodgkin lymphoma (with 
yttrium-90 or indium-111) 
Panitumumab 2006 Human EGFR Colorectal cancer 
Rituximab 1997 Chimeric CD20 Non-Hodgkin’s lymphoma 
Tositumomab 2003 Murine CD20 Non-Hodgkin’s lymphoma 
Trastuzumab 1998 Humanised ErbB2 Breast cancer 
EGFR: Epidermal growth factor receptor; VEGF: Vascular endothelial growth factor. 
 
 Recently, brentuximab vedotin has been approved for the treatment of Hodgkin lymphoma 
and systemic anaplastic large-cell lymphoma. This ADC has been developed by Seattle 
Genetics by conjugating a very potent toxin, monomethyl auristatin E (MMAE), to the anti-
CD30 monoclonal antibody (cAC10) using a protease-cleavable (valine-citrulline) peptide 
linker with a half-life of about six days in mice and 9.6 days in cynomolgus monkey [112].  
Another 25 new ADCs are now in the clinical trials. Some of them are in phase III trials, like 
Trastuzumab-DM1 which is developed to target breast cancer cells using an anti-Her2 
antibody (Herceptin) conjugated with Maytansinoid (DM1) via a succinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linker. Also, Inotuzumab ozogamicin 
has been developed by conjugating the calicheamicin to an anti-CD22 antibody to target non-
Hodgkin lymphoma and is now in a phase III trial. Several ADCs are now in the early clinical 
stages (phase I and II) including CDX-011, which delivers auristatin against melanoma; 
PSMA-auristatin ADC targeting prostate cancer; IMGN388 delivers maytansine against solid 
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tumors αv integrin, BIIB015 targeting cripto expressing tumors and MEDX-1203 delivers 
duocarmycin against CD70 expressing non-Hodgkin lymphoma and renal cell carcinoma [36].  
Conventionally, monoclonal antibodies have been widely used as a ligand for targeted therapy 
as they provide the advantage of high affinity for the target receptors and the relatively long 
half-life. However, the treatment efficiency of the monoclonal antibody based therapy against 
solid tumor remains limited due the low penetration efficiency to deep tumor cells, relatively 
high circulation rate and low clearance rate. Because of these drawbacks, different antibody 
derivatives have been established. The selection of these antibody derivatives is based on 
selecting smaller fragments of the full monoclonal antibody, which can maintain binding 
activity. In this context, a technology of minibody (80kDa), Fab (50kDa), scFv (27kDa), and 
several Fab and scFv-based multimers has been established [113, 114].     
Presently, only three antibody fragments are approved by FDA for human treatment 
comparing to 28 mAbs, and only 54 antibody fragments are in the clinical studies comparing 
to about 450 mAbs. Three classes of antibody fragments composed the 54 clinical trials which 
include 30 Fabs, 19 scFv, and 5 third-generation molecules. Although all the approved 
antibody fragments are Fabs, 22 Fabs clinical studies have been discontinued which account 
71% of all discontinued studies.  Of the 19 scFv which account 35% of antibody fragments in 
the clinical study, 9 scFv have been discontinued.  The latest antibody fragments which 
entered the clinical study are the third generation molecules like VHH-based single-chain, 
miniaturized scFvs and miniaturized antibody and all of them are in the early clinical study 
[115]. 
Out of the 54 clinical trials, 24 fragments have been developed as immunoconjugates by 
conjugating the antibody fragments to effective molecules like cytotoxins or radioisotopes. In 
this context, bacterial toxins have been conjugated to 12 antibody fragments. Staphylococcal 
enterotoxin A has been conjugated to four Fabs, pseudomonas exotoxin conjugated to seven 
scFvs and bouganin conjugated to one Fab. Two of these immunoconjugates are now in 
clinical phase III. Four antibody fragment have been conjugated to interleukin (IL)-2, TNF-α, 
epidermal growth factor and carboxypeptidase 2, respectively, while the other seven 
fragments have been conjugated to different radioisotopes [115, 116].  
 
1.6.1 Photoimmunotherapy  
Photoimmunotherapy is a promising strategy for treatment of cancer that involves the 
targeted delivery of non-toxic photosensitizer which is conjugated to specific cell receptor 
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antibodies. Photosensitizer have been conjugated to different monoclonal antibodies [12, 13, 
20, 117]  and their different fragment types such as single chain Fv antibody (scFv) [15, 21], 
F(ab′)2 [118], and small immunoprotein (SIP) [12] to develop photoimunoconjugates for 
specific delivery of the photosensitizer to target cells. 
 
1.6.2 Antibody mediated chemotherapy payload delivery 
In the recent years, the field of dendritic polymer has been exponentially developed and 
several attempts have been done to use these polymers for treatment of human diseases such 
as cancer and inflammatory diseases.     
Dendritic polymers are highly branched and monodisperse macromolecules with a well-
defined structure. Furthermore, they have a symmetrical architecture and nanometer-size.   
Dendritic polymers are composed of highly branched units, a central core and terminal 
functional groups. This type of architecture gives rise to a number of interesting properties 
comparing to the linear polymers including, the high solubility and the low intrinsic 
viscosities.  Furthermore, these highly branched macromolecules have nanocavities that can 
encapsulate different molecules, including therapeutic agents [119, 120].  
Dendritic polymers present several terminal groups at their surface which have been used to 
conjugate a wide range of therapeutic and/or imaging agents. These functional groups also 
have been used to conjugate these polymers to several cell receptor ligands, such as folic acid, 
peptides, aptamers, monoclonal antibodies and their fragments in order to specifically deliver 
them to target cells [119-122].  
   
1.7 Aptamers  mediated drug delivery 
 Over the past two decades, RNA and DNA aptamers have emerged as a class of therapeutic 
oligonucleotides due to their ability to form specific three-dimensional structures.  
After the first specific selection in 1990 of DNA aptamers by Ellington and Szostak [123] and 
and RNA aptamers by Turek and Gold [124], independently using the systemic enrichment of 
ligands by exponential enrichment (SELEX), aptamers have been selected against more than 
150 different targets molecules including small organics, peptides, proteins, and even 
supramolecular complexes such as viruses or cells [125-132]. 
Compared to the antibody or single chain antibody, aptamers have several distinctive 
properties which make them potential therapeutic agents. Aptamers can be selected against 
any target including toxins and non-immunogenic targets through an in vitro chemical 
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process. They are generally generated by chemical synthesis which reduces the activity 
variation from batch to batch. There is no evidence of inducing the immune system upon in 
vitro and in vivo treatment with aptamers. Also they can be chemically modified with wide 
range of molecules to generate aptamers with diverse properties. Additionally, shelf-life of 
aptamers is unlimited and they can be even transported at room temperature.  
In the last 20 years, several aptamers have been selected as promising pharmaceutical agents 
and used for a variety of therapeutic purposes including anti-viral [133-135], anti-
angiogenesis [136, 137], anti-inflammation [138, 139], anti-coagulation [140, 141] and anti-
proliferation [142-144]. Different cell-internalizing aptamers against wide range of cell 
receptors have been selected and used for drug delivery by receptor-mediated endocytosis. In 
this context, aptamers have been used to deliver chemotherapeutic agents [145-148], 
photosensitizers [19, 149], gold particles [150] and siRNA [87, 90, 93, 95, 96, 151].  
 
1.7.1 Aptamer mediated siRNA delivery against cancer cells  
After anti-PSMA aptamers were developed by Lupold et al., [152] five groups have used 
these aptamers independently for specific siRNA or shRNA delivery.   
In the first approach, Chu et al., [30] described the delivery of 27-mer lamin A/C or GAPDH 
RNA to the PMSA+ prostate cancer (LNCaP) cells mediating specific inhibition of target gene 
expression. In this study, biotinylated A-9 anti-PSMA aptamers and 27-mer RNA with 
disulfide linker were non-covalently conjugated to streptavidin with a 2:2:1 ratio. Despite the 
immunogenicity of streptavidin, this study showed the proof of principle of using aptamers to 
deliver siRNA via receptor-mediated endocytosis.     
Another strategy involves connecting the siRNA to A-10 anti-PSMA aptamer by appending 
the sense strand of siRNA to the 3´ of A-10 aptamer followed by the siRNA antisense strand 
hybridization. With this approach, two siRNA against tumor survival genes (PLK1 and 
BCL2) were successfully delivered to PMSA+ prostate cancer cells and efficiently silenced 
the target genes in vitro and in vivo [90]. 
Later, mono and bivalent aptamer-shRNA were developed to induce cell specific apoptosis.  
In this report, shRNA against eukaryotic elongation factor 2 (EEF2) mRNA was appended to 
the 3´ end of A-10 anti-PSMA aptamer, and to enhance the receptor internalization two types 
of bivalent aptamer-shRNA were developed. In the first construct, shRNA was appended to 
the 3´ end of one aptamer that connected to another aptamer using an RNA spacer and in the 
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second construct, the siRNA sequence was inserted between the two aptamers in the RNA 
spacer portion [93]. 
This study showed two advantages: first of all, siRNA against EEF2 was used which is a 
promising target for RNAi therapy because knocking down the EEF2 lead to rapid arrest of 
protein synthesis, inducing apoptosis and ultimately leading to cancer cell death. Second of 
all, the use of bivalent aptamer increased the silencing efficiency and the toxicity of the 
bivalent aptamer-shRNA chimeras with about 50% compared to the monovalent aptamer-
siRNA chimera.  
One of the biggest challenges for systemic administration is the requirement of high 
therapeutic doses which leads to higher treatment cost and side effects. In this context, the 
therapeutic potential for systemic administration of A10-Plk1 was improved by modifying 
several features. One if these modifications was truncating the original A10 aptamer from 71 
to 39 without affecting the binding efficiency of the aptamer portion. This modification 
reduced the total length of the A10-Plk1 chimera from 96 bases to 64 bases which allows 
efficient chemical synthesis. Also a 20 kDa PEG was added to the 5´-terminus of the siRNA. 
As a result of this modification, the RNA chimera half-life was increased and the dose 
required for tumor growth inhibition was reduced. Furthermore, two nucleotides were added 
to the 3´-overhangs and the positions of guide and passenger siRNA were exchanged. This 
modification lead to an increase in siRNA guided strand loading on the RISC. As a result of 
these modifications, the knockdown efficiency of the new A10-Plk1 chimera was increased 
with about 50-fold comparing to the old A10-Plk1 chimera [153].  
An alternative approach has been described to deliver siRNA against prostate cancer using 
anti-PSMA aptamer. Inhibition of nonsense-mediated messenger RNA decay (NMD) can 
improve cancer vaccination by in situ expression of new and potent antigens in tumor cells 
[91].  In this study anti-PSMA aptamer were appended with Smg1 or Upf2 siRNA and 
systemically administrated to the PMSA+ (CT26) tumor cells implanted mice by vein 
injection. After treating the mice with PSMA aptamer-Smg1 siRNA, 6 of 7 mice rejected the 
implanted tumor. Furthermore, the RNA chimera treatments were found to inhibit lung 
metastasis [91]. 
Increasing evidence indicates that DNA repair pathways are a key determinant of cell survival 
after radiation, and the molecular targeting of these pathways offers therapeutic potential. The 
siRNA-mediated silencing of DNA repair proteins lead to cellular hypersensitivity to 
chemotherapy and radiotherapy [154, 155]. 
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In this context, Ni et al. have screened 249 mRNAs with siRNA library and identified that 
inhibition of the DNA-activated protein kinase, catalytic polypeptide (DNAPK), can sensitize 
prostate cancer cells for ionizing radiation (IR). The selected siRNA sequence was used to 
develop shRNA which was added to the 3´ end of the anti-PSMA aptamer. The results of this 
study proved that combining IR treatment and knocking down of DNAPK by the A30-
DNAPK shRNA chimera dramatically and specifically enhance the PSMA positive prostate 
cancer response to IR in tumor xenografts and normal human prostatic tissue models [33]. 
 
1.8 RNAi target gene 
1.8.1 Elongation factor 2 
The eukaryotic translation elongation factor 2 (EEF-2) is an essential mediator of the 
ribosomal elongation step during mRNA translation and belongs to the GTPase superfamily. 
Elongation factor 2 plays an important role protein biosynthesis by catalyzing GTP-dependent 
translocation of aminoacyl tRNA from the A site to the P site of the ribosome during the 
peptide chain elongation step [156, 157].  
The activity of EEF-2 can be regulated post-translationally by a specific calmodulin-
dependent protein kinase. Pseudomonas A toxin or diphtheria toxin ribosylate ADP of EEF2 
and induce cell apoptosis by inhibiting protein biosynthesis [158, 159]. These approaches 
have been used to develop numerous immunotoxins which were shown to specifically kill 
target cells. A different approach was developed to target EEF2 using specific siRNA against 
EEF2 gene. This study showed that using siRNA against EEF2 knocked down EEF2 
expression efficiently leading to rapid arrest of protein synthesis followed by cell apoptosis 
and cancer cell death [34]. 
 
1.9 Aims and objectives 
The aim of this work was to establish molecular-targeted tumor therapies by conjugating 
therapeutic agents, in this case photosensitizer and chemotherapy payload, to a single chain 
antibody using the SNAP tag technology and siRNA to RNA aptamer. 
The high specificity and affinity of single chain antibody fragments make them a very 
powerful tool to deliver therapeutic agents. However, standard coupling strategies are 
unsuitable for conjugating therapeutic agents to antibodies because there is no reliable way to 
ensure that antibody-therapeutic agent conjugates are produced in the optimal stoichiometric 
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ratio. Furthermore, the chemical properties of the therapeutic agents can alter the 
pharmacokinetic properties and biodistribution of the antibody. Self-labeling proteins such as 
SNAP tag provide a unique conjugation site, allowing the production of a homogeneous 
conjugate preparation. 
In order to investigate the ability of this self-labeling protein to conjugate therapeutic agents, 
fusion proteins containing a single chain antibody fragment scFv425 that bind specifically to 
EGFR and the SNAP-tag will be constructed and expressed in mammalian expression system. 
Another challenge to deliver therapeutic agents is releasing them from the endosomes. 
Therefore we will investigate the ability of cathepsin cleavable adapter that will be inserted 
between scFv-425 and SNAP tag to facilitate releasing of therapeutic agents into cytosol. 
Furthermore, therapeutic agents (photosensitizer and chemotherapy payload) will be modified 
with benzylguanine group and conjugated to the scFv-425-CAT-AD-SNAP fusion protein. 
The binding activity of scFv-425 fusion proteins against EGFR expressing cancer cells and 
self-labeling activity of SNAP tag will be investigated by using commercial BG-modified 
fluorophores, Ce6 or PG-dendrimers. Finally, cytotoxic effect of these scFv-drug conjugates 
will be investigated by evaluating the cell viability and the induction of cell death of EGFR 
expressing cancer cells.  
For the other approach, we will investigate the ability of an anti-αvβ3 RNA aptamer (Apt-
αvβ3) to deliver siRNA against elongation factor 2 gene (siEEF2) and kill αvβ3 expressing 
cancer cells. In order to investigate the potential of this approach, as a first step, aptamer-
siRNA transcripts will be designed and their secondary structures will be analyzed. Then, 
RNAs will be synthesized using in vitro transcription assay. Binding and internalizing activity 
of the aptamer-siRNA construct will be analyzed using flow cytometry and confocal 
microscopy against αvβ3 expressing cancer cells. Finally, the cytotoxic effect of the aptamer-
siRNA transcripts will be analyzed by evaluating cell viability and induction of cell death. 
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Figure 6: Flow chart of the present work. 
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2 Materials and methods  
2.1 Materials  
2.1.1 Equipment 
All devices used in this work are listed in table 3. 
Table 3: Equipment  
Device Model (Manufacturer) 
Centrifuges  
 
MicrofugeR, Avanti J-30I Centrifuge, Allegra 6KR Centrifuge 
(Beckman)  
Biofuge Pico (Heraeus Instruments)  
Picofuge (Stratagene)  
Rotilabo Centrifuge with Butterfly-Rotor (Roth, Karlsruhe, 
Germany)  
Incubators  Thermomixer compact (Eppendorf AG), Incubator (Heraeus 
Instruments)  
Waterbaths  F32, TW20 (Julabo) 
Cell counter  Casy1 (Schärfe System)  
Laminar flow  Hera Safe HS12 (Kendro)  
Gelelectrophoresis and Electroblotting  
 
Mini Protean III gel chamber (BioRad Laboratories, Inc.), Protein 
Gel-Apparatus and supplies Mini PROTEAN II™ (BioRad), Gel 
Air Dryer (BioRad), Mini Trans-Blot Cell (bioRad)  
Cell washer  Dade Serocent (Baxter)  
ELISA plate reader  Elisareader ELx808 (Bio-TEK)  
Flow cytometry FACScalibur (Becton Dickinson),  
PCR-Cyclers  Primus 96 Plus (MWG-Biotech),  
Programmable Thermal Controller PTC-200™ (MJ Research Inc.)  
Transilluminator  
 
Molecular Imager Gel Doc XR System (BioRad)  
 
DNA sequencing  ABI Prism 3700 Capillary-Sequencer (Perkin- Elmer)  
FPLC  Äkta Purifier (Amersham Pharmacia Biotech)  
Photometer  Biophotometer (Eppendorf),  
Liquid handling  Pipetman P (Gilson),  
Multichannel Pipettes (Eppendorf)  
Vortex  Vortex-Genie 2 (Scientific Industries Inc.)  
Sonication  Sonication probe UW2070 (Bandelin  
Electronic)  
Micro tip MS72  
Microscopys  
 
TCS SP5 confocal laser microscopy (Leica), DMIL inverted 
microscopy with mecury fluorescence light source (Leica), 
DM2000 (Leica)  
Flow cytometry  FACScalibur (Becton Dickinson),  
FACS-Vantage with DiVa option (Becton Dickinson)  
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2.1.2 Buffers and media 
Buffers and stock solutions were prepared corresponding to standard procedures using de-
ionized water. With exception of heat-sensitive solutions, which were sterilized using 0.2 μm 
sterilization filter, all other solutions were sterilized by autoclaving (25 min/ 121 °C/ 2 bar). 
The composition of all used buffers is listed in table 4. 
Table 4: Buffers and Media 
Buffer  Composition  Concentration 
TAE (pH 8.2)  Tris  
Glacial acetic acid  
EDTA  
40  
5.7  
10  
mM  
% (v/v)  
mM  
5x OrangeG Loading  
 
OrangeG  
Glycerol  
0.01  
30  
in 1x TAE  
% (w/v)  
% (v/v)  
2x denaturing RNA 
 loading buffer  
Formamide  
EDTA  
SDS  
Bromophenol Blue 
95  
18  
0.025  
0,01  
% (v/v)  
mM  
% (w/v)  
% (w/v)  
10x PBS (pH 7.4)  
 
NaCl  
KCl  
Na2HPO4 x 12H2O  
KH2PO4  
1.37  
27  
81  
15  
M  
mM  
mM  
mM  
TGS (pH 8.3)  
 
Tris-HCl (pH 8.3)  
Glycine  
SDS  
25  
192  
0.1  
mM  
mM  
% (w/v)  
SDS PAGE gel  
(separating gel)  
 
Acrylamide/Bisacrylamide (30/1)  
Tris-HCl (pH 8.8)  
SDS (10 %, w/v)  
TEMED  
APS (20%, w/v)  
x  
375  
0.1  
0.1  
0.1  
mL  
mM  
% (w/v)  
% (v/v)  
% (v/v)  
SDS PAGE gel  
(stacking gel)  
Acrylamid/Bisacrylamide (30/1)  
Tris-HCl (pH 6.8)  
SDS  
TEMED  
APS  
5  
150  
0.1  
0.1  
0.1  
% (w/v)  
mM  
% (m/v)  
% (v/v)  
% (v/v)  
8% denaturing Urea  
PAGE gel (30 mL)  
 
Acrylamide/Bisacrylamide(30/1)  
Urea  
TEMED  
APS, (20%, w/v)  
H2O  
x  
7  
30  
200  
mL (8%) 
M  
μL  
μL  
up to 
30mL  
5x Protein Loading Buffer  Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenolblue  
ß-Mercaptoethanol 
62.5  
30  
4  
0.05  
10  
mM  
% (v/v)  
% (w/v)  
% (w/v)  
% (v/v)  
Coomassie Staining  
Solution  
Coomassie bb. G-250  
Methanol  
Glacial acetic acid  
0.25  
50  
9  
%(w/v)  
% (v/v)  
% (v/v)  
Coomassie Destaining  
Solution  
Methanol  
Glacial acetic acid  
10  
10  
% (v/v)  
% (v/v)  
4x binding buffer (Ni-NTA 
purification, pH 8)  
Na2HPO4  
NaCl  
Imidazole  
200  
1.2  
40  
mM  
M 
mM 
Wash buffer (Ni-NTA) Na2HPO4  50  mM  
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purification, pH 8)  NaCl  
Imidazole  
300  
40  
mM  
mM  
Elution buffer (Ni-NTA 
purification, pH 8) 
Na2HPO4  
NaCl  
Imidazole  
50  
300  
500  
mM  
mM  
mM  
5 x siRNA resuspension buffer 
pH: 7.4  
 
HEPES  
KCl  
MgCl2  
30  
1  
1  
mM  
mM  
mM  
RNA PAGE elution buffer  NaOAc pH: 5,4  0.3  M 
1 x RNA binding buffer 
 (pH 7.4)  
HEPES  
MgCl2  
CaCl2  
20  
1  
1  
mM  
mM  
mM  
1x RNA internalization buffer  
(pH 7.4 ) 
HEPES  
MgCl2  
CaCl2  
Glucose  
20  
1  
1  
16  
mM  
mM  
mM  
mM  
LB medium   
(pH 7.4 ) 
NaCl  
Peptone  
Yeast extract  
1  
1  
0,5  
% (w/v)  
% (w/v)  
% (w/v)  
 
2.1.3 Kits and enzymes  
Unless otherwise noted all endonuclease enzymes were purchased from New England Biolabs 
GmbH (NEB) (Frankfurt am Main, Germany) and used according to the manufacture’s 
instructions. The following kits were used in this work: 
Table 5: Reaction kits   
Application  Kit Company 
In vitro T7-RNA transcription  DuraScribe T7 transcription kit  Biozym  
DNA extraction from agarose gel NucleoSpin ExtractII Macherey-Nagel 
Plasmid DNA preparation NucleoSpin Plasmid Macherey-Nagel 
Cell viability  Cell Proliferation kit II (XTT) Roche applied sciences  
Apoptosis assay  Apo-ONE Caspase-3/7 assay  Promega  
Interferon β detection  Human IFN Beta ELISA Kit  PBL Interferon Source 
 
2.1.4 Synthetic oligonucleotides 
All the synthetic nucleotides were purchased from MWG-Biotech (Ebersberg, Germany). The 
following DNA oligonucleotides were used in this work: 
Table 6: Synthetic oligonucleotides sequences  
Oligo. Name Sequence  
T7-promoter  AAT ACG ACT CAC TAT AG  
T7-Terminator  GCT AGT TAT TGC TCA GCG G  
Apt-αvβ3-assembly 1 GCCTTTTGTGAGCCTCCTGTCGAAGGGTAATCCGCTCGTATA 
AGCCCTTCACAGCGTTG 
Apt-αvβ3-assembly 2 TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAATTCA 
ACGCTGTGAAGGGCT 
5'-Apt-αvβ3 GCCTTTTGTGAGCCTCCTG 
3'-Apt-αvβ3 TAATACGACTCACTATAGGGAGACAAG 
Apt-αvβ3-siEEF2 ATGGACAAGAAGAAGCTTCAATTCTTGTCCATGATGGCGCGCC 
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assembly 1 
Apt-αvβ3-siEEF2 
assembly 2 
CGGATTACCCTTCGACAGGAGGCTCACAAAAGGCGCGCCATCATGGA 
CAAGAATTGAA 
Apt-αvβ3-siEEF2 
assembly 3 
CCTGTCGAAGGGTAATCCGCTCGTATAAGCCCTTCACAGCGTTGAATT 
GAGCGTTT 
Apt-αvβ3-siEEF2 
assembly 4 
TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAATTCAACG 
CTG 
5'-Apt-αvβ3-siEEF2 CCGCGCCATCATGGACAAGAGAAGC 
3'-Apt-αvβ3-siEEF2 TAATACGACTCACTATAGGGAGACAAG 
Apt-αvβ3-siNON  
assembly 1 
GT TAC AGC TTC AAA CGT GAC ACG TTC GGA GAA GCC TTT TGT 
GAG  
Apt-αvβ3-siNON  
assembly 2 
GCG GAT TAC CCT TCG ACA GGA GGC TCA CAA AAG GCT TCT CCG 
AAC GTG TCA CGT TTG  
Apt-αvβ3-siNON  
assembly 3 
CTG TCG AAG GGT AAT CCG CTC GTA TAA GCC CTT CAC AGC GTT 
GAA TTG AGC GTT TAT TC 
Apt-αvβ3-siNON  
assembly 4 
TAA TAC GAC TCA CTA TAG GGA GAC AAG AAT AAA CGC TCA ATT 
CAA CGC TG 
5'-Apt-αvβ3-siNON CCTTCTCCGAACGTGTCACGTTACAGCTTCAACG 
3'-Apt-αvβ3-siNON TAATACGACTCACTATAGGGAGACAAG 
 
2.1.5 RNA sequences 
RNAs were synthesized using in vitro transcription kit (Biozyme, Hessisch Oldendorf, 
Germany). The sequences of RNAs used in this work are listed below: 
 
Table 7: RNAs Sequences  
RNA name Sequence 
Apt-αvβ3  
(84nt) 
GGG AGA CAA GAA UAA ACG CUC AAU UCA ACG CUG UGA AGG 
GCU UAU ACG AGC GGA UUA CCC UUC GAC AGG AGG CUC ACA 
AAA GGC 
Apt-αvβ3-EEF2 
 (133nt) 
GGG AGA CAA GAA UAA ACG CUC AAU UCA ACG CUG UGA AGG 
GUU AUA CGA GCG GAU UAC CCU UCG ACA GGA GGC UCA CAA 
AAG GCG CGC CAU CAU GGA CAA GAA UUG AAG CUU CUU CUU 
GUC CAU GAU GGC GCG G
Apt-αvβ3-siNON  
(135nt) 
GGG AGA CAA GAA UAA ACG CUC AAU UCA ACG CUG UGA AGG 
GCU UAU ACG AGC GGA UUA CCC UUC GAC AGG AGG CUC ACA 
AAA GGC UUC UCC GAA CGU GUC ACG UUU GAA GCU GUA ACG 
UGA CAC GUU CGG AGA AGG 
 
2.1.6 Synthetic siRNA sequences  
Synthetic siRNA were purchased from Qiagen (Hilden, Germany) or Dharmacon (Lafayette, 
USA). Prior to use single siRNA oligonucleotides were resuspended in RNA resuspension 
buffer. The following sequences were used in this work (table 8): 
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Table 8: Synthetic siRNA sequences 
Name siEEF2  
Target eukaryotic elongation factor 2 (eEF2) 
Target DNA sequence CCGCGCCATCATGGACAAGAA 
Accession number NC_000019.8 
RNA sense         GCGCCAUCAUGGACAAGAAdTdT 
RNA antisense UUCUUGUCCAUGAUGGCGCdGdG 
Name Negative control siRNA (siNON) 
Target No target (nonsilencing) 
Target DNA sequence No homolog DNA in human genome 
Accession number --- 
RNA sense         UUCUCCGAACGUGUCACGUdTdT 
RNA antisense ACGUGACACGUUCGGAGAAdTdT 
 
 
2.2 Methods 
2.2.1 Cell culturing  
2.2.1.1 Bacterial Culturing 
Escherichia coli (E. coli) bacteria were cultured in LB medium. For selection of recombinant 
bacteria, cells were cultured on LB-agar plates supplemented with 100 mg/L ampicillin at 
37°C overnight. 
 
2.2.1.2 Culture conditions for mammalian cells  
The human epidermal carcinoma cell line A431 (ATCC no.: CRL-259), human Hodgkin 
lymphoma cell line L540 (DSMZ no.: ACC 72), Chinese hamster ovary cell line CHO-K1 
(ATCC: CCL-6), Human prostate cancer cell line PC-3 (ATCC no. CRL-1435™) and human 
embryonic kidney cell line HEK-293T cells (ATCC: CRL-11268) were cultured in RPMI-
1640 medium supplemented with 2 mM L-glutamine, 10% (v/v) fetal bovine serum (FBS) 
and 100 U/ml penicillin-streptomycin. The human glioblastoma cell line U-87 MG (ATCC 
no. HTB-14™) was grown in Dulbecco's Modified Eagle Medium (DMEM) containing 1g/l 
glucose and 1% MEM non-essential amino acids, 10% (v/v) fetal bovine serum (FBS) and 
100 U/ml penicillin-streptomycin. The human breast carcinoma cell lines MDA-MB-468 
(ATCC: HTB-132) and MDA-MB-231 (ATCC: HTB-26), human cervical carcinoma cell line 
SiHa (ATCC: HTB-35) and human pancreatic carcinoma cell line Panc-1 (ATCC: CRL-1469) 
were cultured in DMEM with 10% (v/v) fetal bovine serum (FBS), 4.5 g/l glucose and 100 
U/ml penicillin-streptomycin. All cells were incubated at 37°C in a 5% CO2 atmosphere. All 
media and additives were obtained from Invitrogen, Darmstadt, Germany. 
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2.2.2 scFv-SNAP tag fusion protein preparation 
2.2.2.1 Molecular cloning and DNA work  
Molecular cloning of DNA was performed using standard procedures described by Sambrook 
et al. 2001. Briefly, SfiI and NotI restriction sites were used to replace the scFv-425 fragment 
in the pMS-scFv-425-SNAP plasmid (constructed by Florian Kampmeier, Fraunhofer IME, 
Aachen) by the scFv-425-CAT-AD fragment from the pMT-scFv-425-CAT-AD-Ang plasmid 
(constructed by Alessa Pardo, Fraunhofer IME, Aachen) generating a eukaryotic expression 
vector (pMS-scFv-425-CAT-AD-SNAP). The vector was composed of a N-terminal binding 
ligand (scFv-425) followed by a cathepsin adapter which contained sequences for endosomal 
and cytosolic cleavage as well as for membrane translocation, [67] and for a C-terminal 
SNAP-tag sequence. The TGA stop codon was inserted right after the His6 tag sequence 
(Figure 6). 
 
2.2.2.1.1 Endonuclease restriction and DNA purification  
DNA restriction was carried out using the manufacturer’s protocol. Digested DNA fragments 
were separated using agarose gel electrophoresis and extracted and purified using NucleoSpin 
Extract II kit (Macherey-Nagel, Düren, Germany). 
 
2.2.2.1.2 DNA Ligation  
DNA ligation was carried out using T4-DNA-Ligase (New England Biolabs NEB Ipswich, 
MA, USA) following the manufacturer’s instructions. Ligation reactions were achieved using 
a 3:1 DNA insert: plasmid vector molar ratio. 
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Figure 7: Schematic illustration of pMS scFv-425-CAT-AD-SNAP vector for the production of scFv-425-CAT-
AD-SNAP fusion protein. Under the control of the cytomegalovirus (CMV) promoter, the pMS-scFv-425-CAT-
AD-SNAP vector encodes the scFv-425-CAT-AD joined in-frame to the SNAP-tag. The fusion proteins are 
secreted by an immunoglobulin kappa leader (Ig-k-L) sequence and a TGA stop codon is placed  after the C-
terminal His6-tag. The additionally transcribed internal ribosome entry site (IVS-IRES) mediates the co-
translational expression of enhanced fluorescent protein (EGFP). 
  
 
2.2.2.1.3 Bacterial transformation  
Competent E.coli DH5α cells were prepared as described by Sambrook et al 2001, and 
bacteria were transformed by heat shock. Competent cells were incubated with the ligation 
mixture for 30 min on ice followed by the heat shock at 42 °C for 90 sec. After an incubation 
for additional 5 min on ice, 800 μl SOC medium were added and cells were incubated for 60 
min at 37°C with shaking (120 rpm). Transformed bacteria were plated on LB agar plates 
supplemented with ampicillin (100 mg/l) and incubated at 37°C overnight. Recombinant 
bacteria were analyzed by plasmid extraction and endonuclease digestion. Finally, DNA 
sequences were verified by DNA sequencing. 
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2.2.2.1.4 Polymerase chain reaction (PCR)  
GoTaq DNA polymerase enzyme (Promega, Mannheim, Germany) was used for amplifying 
all DNA fragments. PCR was carried out according to the manufacturer’s instructions.  
Table 9: PCR reaction mix 
Component Final volume Final conc. 
5X GoTaq Reaction Buffer 10µl 1X (1.5mM MgCl2) 
dNTP mix, 10mM each 1µl 0.2mM each dNTP 
Upstream primer 1µl 0.5µM 
Downstream primer 1µl 0.5µM 
GoTaq DNA polymerase 
(5U/µl) 
0.25µl 1.25U 
Template DNA Xµl <0.5µg/50µl 
Nuclease-Free Water to 50µl  
 
The following PCR program was used for DNA amplification:  
Table 10: DNA amplification program  
 Step Temperature (C°) Time (min) 
1. Initial denaturation  95 5 
2. Denaturation 95 1 
3. Annealing Tp Primer 1 
4. Elongation  72 1 
5. Final elongation  72 10 
Steps 2-4 were repeated 30 times 
 
2.2.2.1.5 Agarose gel electrophoresis  
DNA was analyzed and separated by agarose gel electrophoresis using 0.8-2 % (w/v) agarose 
gel supplemented with 3 μg/ml ethidium bromide at a field strength of 4-5 V/cm. The 
electrophoresis was carried out as described by Sambrook et al. 2001 and 1 μg of 2-Log DNA 
Ladder (New England Biolabs, Ipswich, MA, USA) was used as a DNA standard. Gel Doc 
XR System (BioRad, München, Germany) at a wavelength of 302 nm was used for DNA 
analysis and documentation.  
 
2.2.2.1.6 DNA sequencing  
DNA sequence analyses were carried out at the Fraunhofer IME sequencing facility using an 
“ABI Prism 3700” Capillary-Sequencer (Applied Biosystems) with BigDye™ cycle 
sequencing terminator chemistry and the Applied Biosystems Sequencing Analysis Program. 
DNA-Star program was used to analyze the resulting sequences.   
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2.2.2.2 Recombinant protein expression in HEK-293-T cells  
HEK-293T cells were used to express all recombinant proteins. Eukaryotic expression vectors 
pMS-scFv-SNAP, containing a N-terminal binding ligand (scFv-425 or scFv-Ki4), a C-
terminal SNAP-tag sequence and a His6 tag sequence directly before TGA stop codon were 
generated and were transfected into HEK-293T cells using RotiFect transfection reagent (Carl 
Roth GmbH, Karlsruhe, Germany) following the manufacturer’s instructions. Transfected 
cells were cultured in RPMI-1640 medium supplemented with 2 mM L-glutamine, 10% (v/v) 
fetal bovine serum (FBS) and 100 U/ml penicillin-streptomycin and 100µg/ml Zeocin.  
Binding activities of scFv-SNAP fusion proteins were tested using flow cytometry. Target and 
control cells were incubated with cell-free supernatants for 30 min. The cells were then 
washed twice with 1.8 ml PBS in a conventional cell washer and the binding activity was 
detected with a secondary anti-His5 Alexa 488 antibody (Qiagen, Hilden, Germany).  
The SNAP-tag activity was examined by incubating cell-free supernatants with BG-Vista 
green (Covalys Biosciences AG, Witterswil, Switzerland) for 1h. Labeled proteins were 
visualized after separation by SDS-PAGE with the UV transilluminator Gel Doc XR gel 
documentation system (Bio-Rad Laboratories, München, Germany). 
 
2.2.2.3 Polyacrylamide gel electrophoresis 
Recombinant proteins were separated using SDS-PAGE electrophoresis. Before separation, 
protein samples were mixed with 5x protein loading buffer and denatured for 5 min at 95°C 
followed by loading onto 12% SDS gel and separation at 140 V for 1 h. After separation, 
labeled proteins were visualized either with a UV transilluminator Gel Doc XR gel 
documentation system (Bio-Rad Laboratories, München, Germany) or a CRi Maestro imaging 
system (CRi, Woburn, MA, USA) using the blue and yellow filter sets. Proteins were also 
analyzed by staining with Commassie Brilliant blue.  
 
2.2.2.4 Recombinant protein purification 
His6-tagged fusion proteins were purified from cell-free supernatants on an Äkta FLPC 
system with a 5-mL Ni-NTA Superflow cartridge (Qiagen, Hilden, Germany) after 
equilibration with 4x buffer (200 mM NaH2PO4, 1.2 M NaCl, 40 mM imidazole, pH 8). 
Bound His-tagged proteins were eluted with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
250 mM imidazole, pH 8). After elution, proteins were dialyzed at 4°C overnight against PBS 
containing 1 mM Dithiothreitol (DTT) (Carl Roth GmBH, Karlsruhe, Germany). Ectoine 
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cryopreservative was added to a final concentration of 50 mM and aliquots were stored at –
20°C. 
 
2.2.2.5 Protein labeling  
Purified SNAP-tag fusion proteins were conjugated with BG-modified Vista Green or 647 
dyes (Covalys Biosciences AG, Witterswil, Switzerland) by incubation in the dark with a 1.5-
fold molar excess of dye for 2 h at room temperature. Residual dye was removed by gel 
filtration chromatography using zeba spin desalting columns, 7K MWCO (Thermo Fisher 
Scientific, Rockford, IL).  To determine the coupling efficiency photometrically, the 
theoretical extinction coefficients of the proteins and the extinction coefficients of the 
fluorescence dyes were used.  
Labeled proteins were visualized after separation by SDS-PAGE as described in 2.2.2.9 with 
a CRi Maestro imaging system (CRi, Woburn, MA, USA) using the blue and yellow filter 
sets.  
 
2.2.2.6 CAT-AD digestion with cathepsin B  
The scFv-425-CAT-AD-SNAP and scFv-425-SNAP fusion proteins were digested using 
cathepsin B enzyme (Enzo Life Sciences, Lörrach, Germany). Briefly, 10 µg of fusion protein 
labeled with BG-Vista green dye were incubated with three different amount  (0.025, 0.1 and 
0.25) µg of cathepsin B enzyme for 2 h at 37°C. After that fusion proteins were visualized 
after separation by SDS-PAGE with a UV transilluminator Gel Doc XR gel documentation 
(Bio-Rad Laboratories, München, Germany). Proteins were also analyzed by staining with 
Commassie Brilliant blue.  
 
2.2.2.7 Flow cytometry analysis of recombinant proteins 
The binding efficiency of scFv-425-CAT-AD-SNAP and scFv-425-SNAP fusion proteins was 
determined by flow cytometry using a FACSCalibur device and the CellQuest software 
(Becton & Dickinson, Heidelberg, Germany). EGFR+ cell line A431 was used to test the 
binding efficiency of scFv-425-CAT-AD-SNAP and scFv-425-SNAP, while EGFR– cell line 
L540 was used as negative control. The control fusion protein scFv-Ki4-SNAP recognizes the 
antigen CD30 and should therefore bind to L540 cells but not to the A431 cell line. 
Approximately 4×105 cells were incubated in 200 μl PBS containing 0.5 μg of labeled protein 
for 30 min on ice. Anti-Penta-His monoclonal antibody conjugated to Alexa-488 (Qiagen, 
 | 30 
 
Hilden, Germany) was used as the secondary antibody. The cells were then washed twice with 
1.8 mL PBS in a conventional cell washer and analyzed by flow cytometry. To exclude 
nonspecific staining of the secondary antibody, omission of the His-tagged fusion protein 
served as control. 
 
2.2.2.8 Confocal microscopy of recombinant proteins 
Cells were prepared as described in 2.2.2.13. Binding efficiency was determined by 
incubating EGFR+ cell line (A431) with labeled fusion proteins for 30 min on ice, EGFR– cell 
line L540 was used as negative control. Internalization was monitored by incubating cells 
with the labeled fusion proteins for 30 min at 37°C. Cells were visualized with a TCS SP5 
confocal microscopy (LEICA Microsystem, Wetzlar, Germany). 
 
2.2.3 Specific delivery of photosensitizer using scFv-SNAP tag fusion protein 
2.2.3.1 Modification of the photosensitizer chlorin e6 with benzylguanine 
The carboxyl groups of Ce6 (Porphyrin Products, Logan, UT) were modified with 
benzylguanine by mixing 2 mg Ce6 in dimethylformamide for 30 min at room temperature 
with 5-fold molar excess of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC) and sodium salt of hydroxysulfosuccinimide (sulfo-NHS) (Sigma-Aldrich, St Louis, 
MO). The activated mixture was then mixed with a 2-fold molar excess of the benzylguanine 
linker BG-PEG24-NH2 (Covalys Biosciences AG, Witterswil, Switzerland) in the dark at 
room temperature overnight. The modified Ce6 was purified by HPLC using a Shimadzu 
Prominence HPLC system and a 2.5 µm (4.6 x 50 mm) Water XBridgeTM OSTC18 column 
(Waters, Milford, MA) at a flow rate of 1 ml/min. Separations were carried out using a 20-
min gradient from 0.1 M Triethylammonium acetate (TEAA) to 100% acetonitrile, elution 
profile monitored at 260 and 280 nm. The masses of Ce6, BG-PEG24-NH2 and BG-PEG24-
Ce6 were confirmed using a Micromass QTOFII mass spectrometer with an electrospray ion 
source Advion Nanomate (Advion, Ithaca, NY, USA). 7µl sample volume, 1.4 kV. Accurate 
masses were derived from mass spectra obtained in the range 300–2500 m/z using the 
MaxEnt3™ algorithm  (Micromass) in the range of 400–2000 Da. 
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2.2.3.2 Protein labeling with BG-PEG24-Ce6 
The purified SNAP-tag fusion proteins were conjugated with BG-modified Ce6 by incubation 
in the dark with a 3-fold molar excess of BG-PEG24-Ce6 for 2 h at room temperature. 
Residual BG-PEG24-Ce6 was removed by gel filtration chromatography using zeba spin 
desalting columns, 7K MWCO (Thermo Fisher Scientific, Rockford, IL).  The theoretical 
extinction coefficient of the proteins and the extinction coefficients of the chlorin e6 were 
used to determine the coupling efficiency photometrically. 
Labeled proteins were visualized after separation by SDS-PAGE as described in 2.2.2.10 with 
a CRi Maestro imaging system (CRi, Woburn, MA, USA) using the blue and yellow filter 
sets.  
 
2.2.3.3 Flow cytometry analysis  
The binding efficiency of the fusion proteins labeled with BG-modified Vista green dye or 
BG-modified Ce6 was determined by flow cytometry using a FACSCalibur device and 
CellQuest software (Becton & Dickinson, Heidelberg, Germany). EGFR+ cell lines A431, 
MDA-MB468, MDA-MB-231 and SiHa were used to test the binding efficiency of scFv-425-
CAT-AD-SNAP and EGFR– cell lines L540 and CHO-K1 were used as negative controls. 
The control fusion protein scFv-Ki4-SNAP recognizes the antigen CD30 and should therefore 
bind to L540 cells but not to the other cell lines. Approximately 4×105 cells were incubated in 
200 μL PBS containing 0.5 μg of labeled protein for 30 min on ice. The cells were then 
washed twice with 1.8 ml PBS in a conventional cell washer and analyzed by flow cytometry. 
 
2.2.3.4 Confocal microscopy 
The binding and internalization efficiency of the fusion proteins labeled with BG- modified 
Ce6 was determined by a TCS SP5 confocal microscopy (LEICA Microsystem, Wetzlar, 
Germany). Cells were prepared as described in 2.2.2.13. Binding efficiency was determined 
by incubating cells with the labeled fusion proteins for 30 min on ice. Internalization was 
monitored by incubating cells with the labeled fusion proteins for 30 min at 37°C.  
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2.2.3.5 Phototoxicity of scFv-425-SNAP-Ce6 
A431, MDA-MB468, MDA-MB-231, SiHa and CHO-K1 cells (2x104) were cultured 
overnight in 96 well plates at 37°C, washed twice in PBS and then treated with increasing 
concentrations of either Ce6, scFv-425-CAT-AD-SNAP-Ce6, scFv-425-SNAP-Ce6 or Ki4-
scFv-SNAP-Ce6, followed by incubation for 3 h at 37°C. Control cultures were incubated 
with 500 μg/ml Zeocin instead of the photosensitizer. The cells were washed three times with 
PBS followed by addition of 100µl of fresh phenol red free medium.  The cells were then 
irradiated with visible light (VIS) plus water-filtered infrared light A (wIRA) using the 
Hydrosun type 505 radiator with a water-containing cuvette and an orange filter OG590 with 
a spectrum in the range of 580–1400 nm (Hydrosun Medizintechnik GmbH, Müllheim, 
Germany). The irradiation experiments were performed taking into account the physical and 
photobiological laws described by Piazena and Kelleher (16). The cells were placed in a 
water-bath and the temperature was controlled during irradiations (total irradiance: 112 
mW/cm2, dose: 25 J/cm2a VIS, 76 J/cm2 wIRA, exposure time: 15 min). Thereafter, cells 
were incubated for further 24 h at 37°C in a 5% CO2 atmosphere.  
Cell viability was determined using the XTT cell proliferation kit II (Roche, Mannheim 
Germany), 24 h after irradiation. Cells were incubated with 2,3-bis(2-methoxy-4-nitro-
5sulphonyl)-5[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide reagent (1mg/ml) and 
incubated for 4 h at 37°C. Reduction of XTT to formazan by viable tumor cells was 
monitored colorimetrically at an absorbance wavelength of 450 nm and a reference 
wavelength of 630 nm using an ELISA plate reader ELx808 (Bio-TEK, Bad Friedrichsahll, 
Germany).  
Caspase-3/7 activity in cell lysates was determined using the Apo-ONE Caspase-3/7 assay 
(Promega, Mannheim, Germany) 24 h after light activation. Briefly, cells were incubated with 
100 µl of Apo-ONE reagent for 6 h before fluorescence readings were taken with an ELISA 
plate reader ELx808 (Bio-TEK, Bad Friedrichsahll, Germany) using an excitation wavelength 
of 485 nm and an emission wavelength of 535 nm. The concentration of reactive oxygen 
species (ROS) was determined by measuring the 485/535 nm fluorescence ratio of 
H2DCFDA (Invitrogen, Darmstadt, Germany). 2x104 cells were incubated in the presence of 
50 nM Ce6 or 200 nM scFv-425-SNAP-Ce6 and 10 µM H2DCFDA for 30 min in PBS 
containing 1% FCS. The cells were washed twice with warm PBS containing 2.5% FCS, 
cultured for 2 h in RPMI-160 medium and illuminated as described above. Fluorescence 
readings were taken directly after illumination. A blank probe (cells and medium) reading was 
used as the background and subtracted from all sample readings. 
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2.2.4 Specific delivery of polyglycerol-Doxorubicin dendrimers conjugated to the 
scFv-SNAP recombinant protein against cancer cells 
2.2.4.1 Coupling of SNAP-tag fusion proteins to polyglycerol-doxorubicin conjugates 
Benzylguanin-modified polyglycerol dendrimers (BG-PG-Doxo-IDCC) loaded with 
doxorubicin (Doxo) and indodicarbocyanine-maleimide (IDCC) fluorophore were provided 
by a collaboration partner (Dr. M. Calderon, Institute for Chemistry and Biochemistry, AG-
Haag, Freie Universität Berlin). Each particle has a molar mass of 10 kDa containing 20% 
amino loading and was conjugated to 2 molecules of benzylguanine-maleimide, one molecule 
of IDCC, 30 molecules of poly (ethylenglycol), and 5 molecules of Doxo conjugated via an 
acid sensitive bond, which is stable at pH 7, but rapidly releases the doxorubicin at pH 5 
(Figure 7).  
The BG modified polyglycerol dendrimers were conjugated to the scFv-425-CAT-AD-SNAP 
tag fusion protein by incubating them for 2 h at room temperature in 3:1 ratio. Conjugated 
protein was purified from unconjugated protein and free polyglycerol dendrimers on an Äkta 
FLPC system with a 24-mL superdex 75 column (GE Healthcare München, Germany) and 
elution profile monitored at 260 and 650 nm.  
 The coupling efficiency was evaluated indirectly by separating the purified fractions by SDS-
PAGE. The coupling efficiency was evaluated indirectly by evaluating the unconjugated 
protein using aida image analyzer software. Furthermore the SDS-PAGE was visualized with 
a CRi Maestro imaging system (CRi, Woburn, MA, USA) using the blue and yellow filter 
sets. 
 
2.2.4.2 Flow cytometry analysis  
Flow cytometry analysis was used to evaluate the binding efficiency of scFv-425-CAT-AD-
SNAP-PG-Doxo-IDCC. Three EGFR expressing cancer cell lines (A431, MDA-MB-468 and 
Panc-1) and one EGFR– cell line (CHO-K1) were used to analyze the binding efficiency of 
scFv-425-CAT-AD-SNAP-PG-Doxo-IDCC. Approximately 4×105 cells were incubated in 
200 μl PBS containing 0.5 μg of conjugated protein at 4°C  or equivalent amount of PG-
Doxo-IDCC particles for 30 min on ice or 37°C. The cells were then washed twice with 1.8 
mL PBS in a conventional cell washer and analyzed by flow cytometry using a FACSCalibur 
device and CellQuest software (Becton & Dickinson, Heidelberg, Germany). 
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Figure 8: Schematic demonstration of Benzylguanine-modified polyglycerol dendrimers loaded with 
doxorubicin and IDCC dye. 
 
2.2.4.3 Confocal microscopy 
The TCS SP5 confocal microscopy (LEICA Microsystem, Wetzlar, Germany) was used to 
evaluate the binding and internalization efficiency of the fusion proteins conjugated with BG- 
modified PG-Doxo-IDCC. Cells were prepared as described in 2.2.2.13. Binding efficiency 
was analyzed by incubating the cells with the conjugated fusion proteins or unconjugated PG-
Doxo-IDCC dendrimers for 30 min on ice and the internalization was monitored by 
incubating cells with the conjugated fusion proteins or PG-Doxo-IDCC dendrimers for 30 min 
at 37°C.  
 
2.2.4.4 Cytotoxic activity of scFv-425-CAT-AD-SNAP-PG-Doxo 
Cell viability was analyzed using a cell proliferation kit based on 2,3-bis-(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) (Roche, Mannheim Germany). Briefly, 
2x104 cells of A431, MDA-MB-468, Panc-1 and CHO-K1 were seeded in 96-well plates and 
incubated for 24 h at 37°C. The cells were treated with different concentrations (0, 100, 200, 
400, 800 and1600 nM) of scFv-425-CAT-AD-SNAP-PG-Doxo, PG-Doxo and free 
doxorubicin followed by incubation for 48 h at 37°C. As a positive control 5 μg/ml of zeocin 
was used. After incubation, cells were treated for 4 h with XTT solution (1mg/ml) at 37°C. 
Cell viability was evaluated by colorimetric monitoring of the reduction of XTT to formazan 
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at an absorbance wavelength of 450 nm and a reference wavelength of 630 nm using the 
ELx808 microtiter plate reader (BioTek Instruments GmbH, Bad Friedrichshall, Germany).  
 
2.2.5 Aptamer mediated siRNA delivery  
2.2.5.1 DNA template preparation for in vitro RNA transcription  
2.2.5.1.1 Predicting RNA secondary structure 
The secondary structures of the anti-αvβ3 integrin aptamer (Apt-αvβ3) [86], the aptamer-
siRNA construct (Apt-αvβ3-siEEF2) and the control construct Apt-αvβ3-siNON (Table 7) 
were predicted using the MFOLD RNA structure program 
(http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form). Evaluation of the most stable 
structures was done based on the lowest free energies for each construct. 
 
2.2.5.1.2 Assembly PCR  
Template DNAs for Apt-αvβ3-siEEF2 and Apt-αvβ3-siNON containing the T7 RNA 
polymerase promoter sequence were designed using the Assembly PCR Oligo Maker program 
(http://startrek.ccs.yorku.ca/~pjohnson/AssemblyPCRoligomaker.html) [160]. The template 
DNA for Apt-αvβ3-siEEF2 and Apt-αvβ3-siNON were synthesized by assembly-PCR using 
four overlapping primers. The following PCR mixture and PCR program were used for 
amplifying the DNA templates for in vitro RNA transcription. 
Table 11: Assembly PCR mixture  
Component Final volume Final conc. 
5X GOTaq Reaction Buffer 20µl 1X (1.5mM MgCl2) 
dNTP mix, 10mM each 2µl 0.2mM each dNTP 
Assembly primers (each) 2.5µl 2.5µM (each) 
GoTaq DNA polymerase (5U/µl) 0.5µl 2.5U 
Nuclease-Free Water to 100µl  
 
 
Table 12: Assembly PCR program 
 Step Temperature (C°) Time (min) 
1. Initial denaturation  95 5 
2. Denaturation 95 1 
3. Annealing 55 1 
4. Elongation  72 1 
5. Final elongation  72 10 
Steps 2-4 were repeated 15 times 
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For full-length DNA amplification, 1µl of the assembly PCR product was used as template as 
described in 2.2.2.5.  
 
2.2.5.1.3 In vitro transcription  
The Apt-αvβ3-siEEF2 and Apt-αvβ3-siNON transcripts were synthesized in vitro from a 
dsDNA template in a 20-µl reaction volume using the DuraScribe T7 Transcription Kit 
(Epicentre, Madison, WI). The reaction comprised 1g DNA template, 5 mM ATP and GTP, 
5 mM 2'F-dCTP and 2'F-dUTP, and 2 µl DuraScribe T7 enzyme mix. Reactions were carried 
out for 6 h at 37°C before adding DNase I for 20 min at 37°C. The RNA products were 
purified by denaturing (7 M urea) 8% polyacrylamide gel electrophoresis. RNA bands were 
excised and RNA was eluted in 0.3 M sodium acetate for 1 h at 60°C and recovered by 
ethanol precipitation. 
 
2.2.5.1.4 Fluorescence labeling of RNA 
The 5'-end of substrate RNA strands were modified during in vitro transcription using 25 mM 
guanosine-5'-O-monophosphothioate (GMPS), 2.5 mM each NTP and 2 µl DuraScribe T7 
enzyme mix. The in vitro transcript was digested with DNaseI for 20 min, and the GMPS 
thiol group was reduced with 100 mM DTT. After purifying the RNA, the reduced thiol group 
was labeled with the fluorescent probe 5'-iodoacetamidofluoresceine (IAF) in labeling buffer 
(10 mM EDTA, 1 M urea, 100 mM Tris-HCl pH 7.4) also containing 10% (v/v) 
dimethylformamide overnight at 4°C. 
Labeled transcripts were purified using HPLC (Shimadzu Prominence HPLC system) and 
elution profiles were monitored at 260 and 480 nm. A Water XBridgeTM OSTC18, 2.5µm (4.6 
x 50 mm) column (Waters, Milford, MA) was used for RNA analysis and purification. The 
mobile phase flow rate was 1 ml/min. During the analytical and purification run, gradient 
elution was carried out using mobile phases A (0.1 M triethylammonium acetate (TEAA) and 
5% acetonitrile) and B (0.1 M TEAA and 30% acetonitrile). The RNA was separated using a 
20-min gradient of B from zero to 100%. 
 
2.2.5.2 Flow cytometry analysis of aptamer-siRNA 
Apt-αvβ3-siEEF2 RNA was refolded by heating for 5 min at 80°C, then slowly cooled to 
37°C and incubated at 37°C for 10 min in 1x HEPES buffer (20 mM HEPES, 150 mM NaCl, 
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1 mM MgCl2, 1 mM CaCl2, pH 7.4). Approximately 4×105 cells of U-87 MG, SiHa, PC-3 and 
HEK-293T cells were incubated either with 200 nM of labeled RNA in 1x HEPES buffer or 
with the Phycoerythrin (PE)-labeled monoclonal anti-human αvβ3 integrin antibody (R&D 
Systems GmbH, Wiesbaden, Germany) for 30 min on ice. The cells were then washed twice 
with 1.8 ml 1x HEPES buffer and analyzed using a FACSCalibur device (Becton & 
Dickinson, Heidelberg, Germany).  Data analysis was performed with CellQuest Software 
(Beckton Dickenson). 
 
2.2.5.3 Confocal miscroscopy of aptamer-siRNA 
U-87 MG, SiHa, PC-3 and HEK-293T cells (4×105) were washed twice with 1.8 ml 1x 
HEPES buffer and incubated with 200 nM IAF-labeled RNA in 1 x HEPES binding buffer 
supplemented with 16 mM glucose. The binding controls were kept on ice. All other samples 
were incubated in the dark at 37°C for 60 min. At the end of the incubation, the cells were 
washed twice as described in 2.2.5.6 and the cell suspension was incubated for 5 min with 2 
μl of a 1:100 diluted Draq5 solution (Biostatus, Shepshed, UK) to counterstain the nucleus. 
All images were captured using a TCS SP5 confocal microscopy (LEICA Microsystem, 
Wetzlar, Germany). 
 
2.2.5.4 Cytotoxic activity of aptamer-siEEF2 
Cell viability was determined using a cell proliferation kit based on 2,3-bis-(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) (Roche, Mannheim Germany). 
Briefly, aliquots of 2x104 U-87 MG, SiHa, PC-3 and HEK-293T cells were seeded in 96-well 
plates and incubated overnight at 37°C. The cells were treated with different concentrations 
(0, 100, 250, 500, 1000 and 2000 nM) of siEEF2, siNON, Apt-αvβ3-siEEF2 and Apt-αvβ3-
siNON followed by incubation for 48 h at 37°C, and 5 μg/ml zeocin was used as a positive 
control. After incubation, cells were treated for 4 h with XTT solution (1mg/ml) at 37°C. Cell 
viability was analyzed colorimetrically by monitoring the reduction of XTT to formazan at an 
absorbance wavelength of 450 nm and a reference wavelength of 630 nm using the ELx808 
microtiter plate reader (BioTek Instruments GmbH, Bad Friedrichshall, Germany).  
The induction of apoptosis in U-87 MG, SiHa, PC-3 and HEK-293T cells was measured using 
the Apo-ONE Caspase-3/7 assay (Promega, Mannheim, Germany) according to the 
manufacturer’s instructions. Briefly, cells were seeded in 96-well plates at a density of 2x 104 
cells per well in 100 µl medium and allowed to attach overnight at 37°C. Different 
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concentrations (0, 100, 250, 500, 1000 and 2000 nM) of siEEF2, siNON, Apt-αvβ3-siEEF2 
and Apt-αvβ3-siNON were added to the cells, and 5 µg/l zeocin was used as a positive 
control. After 48 h incubation at 37°C, 100µl of Apo-ONE reagent containing a fluorogenic 
substrate was added to the cells. After 6 h incubation at room temperature, the proteolytic 
activity of caspase 3/7 was measured fluorimetrically (excitation wavelength 485 nm, 
emission wavelength 535 nm) using a microtiter plate reader.  
 
2.2.5.5 Interferon assay 
Interferon β induction was measured using the human interferon β ELISA kit (PBL, 
Biomedical Laboratories) consisting of two interferon β specific monoclonal antibodies 
following the manufacturer’s recommendations. Briefly, U-87 MG, SiHa and PC-3 cells were 
incubated for 48 h at 37°C after exposure to either 2 µM Apt-αvβ3-siEEF2 or Apt-αvβ3-
siNON. The cell culture supernatant (100 µl) was then transferred to a pre-coated ELISA 
plate with β specific monoclonal antibodies and incubated for 24 h at room temperature. 
Different concentrations (25, 50, 500, 1000 and 2000 pg/ml) of human interferon β were used 
as positive controls. Bound interferon β was detected by specific antibodies provided with the 
ELISA kit.  
 
2.2.6 Data analysis 
Statistical analysis and curve fitting were performed with GraphPad Prism software 
(GraphPad software). Data represent the average of triplicates ± SEM. Student’s t test and 
two-way analyses of variance were used to assess the significance of independent 
experiments, with P < 0.05 as the threshold for statistical significance. 
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3  Results 
3.1 Specific delivery of therapeutic agents using scFv-SNAP tag fusion 
protein  
3.1.1 scFv-SNAP tag fusion protein preparation 
3.1.1.1 Expression, purification and functional analysis of scFv-SNAP-tag fusion 
proteins 
The coding sequence for the EGFR-specific scFv-425-CAT-AD fragment [53] was ligated to 
the pMS-SNAP bicistronic vector to generate the complete scFv-425-CAT-AD-SNAP 
cassettes, as shown in (Figure 8A). The pMS-SNAP bicistronic vector which contains the 
coding sequence for scFv-425-SNAP and scFv-Ki4-SNAP [161] was kindly provided by 
Florian Kampmeier Fraunhofer IME, Aachen) (Figure 8A). The constructs were introduced 
into HEK-293T cells by transfection and transformed cells were identified by selection on 
zeocin and by monitoring green fluorescent protein (GFP) activity. Fusion proteins were 
isolated from the culture supernatant by affinity chromatography to a final purity of ~90% by 
affinity chromatography (using the C-terminal His6 tag) and the final yield of protein was 
more than 18 mg/L supernatant (Figure 8B).  
The activity of the SNAP-tag was confirmed in each of the fusion proteins by treating the 
unprocessed culture supernatant, the flow through and the elution from the chromatography 
steps separately with BG-modified Vista Green (Figure 8C).  
 
3.1.1.2 Labeling of recombinant proteins with BG-fluorophores  
The functionality of the SNAP-tag in both scFv-425-CAT-AD-SNAP and scFv-425-SNAP 
was tested by coupling them to two different BG-modified fluorescent dyes (BG-Vista green 
and BG-647). Both dyes coupled efficiently to the recombinant proteins and no significant 
reduction in the self-labeling activity of SNAP tag was observed (Figure 9). The theoretical 
extinction coefficients of the proteins and the extinction coefficients of the fluorescence dyes 
were used to determine the coupling efficiency photometrically, which revealed a labeling 
efficiency of 85–90% after an 2 h incubation at room temperature. 
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 Figure 9: Construction and expression of the SNAP-tag fusion proteins. Schematic diagram of the bicistronic 
eukaryotic expression cassettes for scFv-425-SNAP, scFv-Ki4-SNAP and scFv-425-CAT-AD-SNAP (A). Under 
the control of the cytomegalovirus (CMV) promoter, the pMS-scFv-Ki4-SNAP vector encodes the scFv-Ki4 
joined in-frame to the SNAP-tag. The scFv-425-CAT-AD-SNAP vector is the same as described above, but the 
binding domain is replaced by scFv-scFv and CAT-AD fragment is inserted between the scFv-425 and the 
SNAP fragments. The fusion proteins are secreted by an immunoglobulin kappa leader (Ig-k-L) sequence, and a 
TGA stop codon is placed immediately after the C-terminal His6-tag. The additionally transcribed internal 
ribosome entry site (IVS-IRES) mediates the cotranslational expression of enhanced fluorescent protein (EGFP) 
(B) Coomassie brilliant blue-stained SDS-PAGE of the purification fractions 1-4 (eluted with an imidazole 
concentration up to 250 mM) of scFv-425-CAT-AD-SNAP protein and (C) corresponding BG-Vista Green in-
gel UV visualization of the fusion protein (indicated by a black arrow). M: Prestained Protein Marker, Broad 
Range (7-175 kDa), 5: Flow through, 6: Supernatant of HEK-293T cells [54].  
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Figure 10: Recombinant protein labeling with BG-fluorophores. (A) Coomassie brilliant blue-stained SDS-
PAGE of scFv-425-CAT-AD-SNAP or scFV-425-SNAP fusion proteins coupled with BG-647 or BG-Vista 
Green and (B) corresponding in-gel fluorescence visualization of the fusion proteins. The different dye spectra 
were unmixed based on their spectral patterns using CRi Maestro multispectral imaging system. M, Prestained 
Protein Marker, Broad Range (7-175 kDa); (1) scFv-425-CAT-AD-SNAP labeled with BG-647, (3) with BG-
Vista Green, (2) scFv-425-SNAP labeled with BG-647 and (4) with BG-Vista Green. 
 
3.1.1.3 Cathepsin cleavable adapter digestion with cathepsin B enzyme  
In order to facilitate the release of therapeutic agents from the endosomes, cathepsin sensitive 
peptide adapter was inserted between the scFv-425 and the SNAP fragments producing the 
scFv-425-CAT-AD-SNAP fusion protein. The sensitivity of this adapter to cathapsin B 
enzyme was confirmed in vitro by incubation at 37°C for 2 h. The cathepsin sensitive peptide 
adapter (10 µg) was digested efficiently using 0.25µg of cathepsin B enzyme. However scFv-
425-SNAP fusion protein showed lower unspecific sensitivity to the cathepsin B enzyme in 
high concentration (Figure 10).  
 
3.1.1.4 Flow cytometry analysis of scFv-425-CAT-AD-SNAP 
The binding activity of scFv-425-CAT-AD-SNAP and scFv-425-SNAP fusion proteins was 
confirmed by flow cytometry using a target cell line expressing EGFR (A431), and a control 
cell line lacking this antigen but expressing CD30 (L540). Binding was detected with a 
secondary anti-His5 Alexa 488 antibody. Flow cytometry data confirmed the rapid and 
efficient binding of scFv-425-CAT-AD-SNAP and scFv-425-SNAP specifically to EGFR+ 
target cells, whereas no fluorescence signal was detected when fusion proteins were incubated 
with L540 cells at the same conditions. Furthermore no significant reduction in the binding 
activity of scFv-425-CAT-AD-SNAP was observed compared to scFv-425-SNAP (Figure 
11). 
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Figure 11: scFv-CAT-AD-SNAP and scFv-425-SNAP fusion proteins digested with cathepsin B enzyme. 10 µg 
of fusion proteins labeled with BG-Vista green dye were incubated with three different amounts 0.025 µg (A), 
0.1 µg (B) and 0.25 µg (C) of cathepsin B enzyme for 2 h at 37°C. The fusion proteins were visualized after 
separation by SDS-PAGE with a UV transilluminator Gel Doc XR gel documentation system (right panel). 
Furthermore proteins were analyzed by staining the gel with the Commassie Brilliant blue (left panel).  
 
3.1.1.5 Internalizing of scFv-CAT-AD-SNAP to the EGFR expressing cells 
The binding and internalization activity of the scFv-425-CAT-AD-SNAP and scFv-425-
SNAP proteins were confirmed using confocal microscopy using a EGFR expressing cell line 
(A431). The scFv-425-CAT-AD-SNAP was labeled with BG-Vista Green and scFv-425-
SNAP was labeled with BG-647. Confocal microscopy results confirmed the homogeneous 
and strong membrane staining on A431 cells using both scFv-425-CAT-AD-SNAP and scFv-
425-SNAP labeled proteins (Figure 12). The labeled fusion protein was found to rapidly and 
efficiently internalize into A431 cells after an incubation of 30 min at 37°C but not at 4°C. 
Confocal microscopy results did not show any significant differences in binding and 
internalization activity between the scFv-425-CAT-AD-SNAP and scFv-425-SNAP (Figure 
12). 
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Figure 12: Flow cytometric binding analysis of scFv-425-CAT-AD-SNAP and scFv-425-SNAP to EGFR+ A431 
and EGFR- L540 cells. Filled gray curves represent untreated cells. Cells were incubated with 0.5 µg/ml of the 
purified fusion protein scFv-425-CAT-AD-SNAP (light gray curve), or scFv-425-SNAP (black curve). Fluor 
488-conjugated anti-Penta-His monoclonal antibody was used as the secondary antibody. To exclude nonspecific 
staining of the secondary antibody, omission of the His-tagged fusion protein served as control (dotted black 
curves).  
 
 
Figure 13: Binding and internalization of scFv-425-CAT-AD-SNAP-Vista Green and scFv-425-SNAP-647 
analyzed using confocal microscopy. Confocal images were obtained for the EGFR+ cell line A431. The cells 
were incubated with 0.5 µg scFv-425-SNAP-647 (A), scFv-425-CAT-AD-SNAP-Vista green (B) and with both 
scFv-425-SNAP-647 and scFv-425-CAT-AD-SNAP-Vista green (C) for 30 min at 4°C or 37°C. (1) Vista Green 
fluorescence signal; (2) 647 fluorescence signal (3) transmitted light; (4) overlay of fluorescence signal and 
transmitted light.  
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3.1.2 Specific delivery of photosensitizer using scFv-SNAP tag fusion protein 
3.1.2.1 Modification of the photosensitizer chlorin e6 with benzylguanine 
The photosensitizer chlorin e6 (Ce6) was successfully modified using N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), the sodium salt of 
hydroxysulfosuccinimide (sulfo-NHS) and a BG-PEG24-NH2 linker. Ce6 carboxyl groups 
were modified to a BG group (Figure 13), and the BG-modified Ce6 was successfully purified 
using reverse phase chromatography (Figure 14). Ce6 modification with a BG group was 
confirmed by mass spectrometry. The accurate masses of Ce6 (597.215 Da), BG-PEG24-NH2 
(1398.761 Da) and BG-PEG24-Ce6 (1979.004 Da) were detected on a Micromass QTOFII 
mass spectrometer, which confirmed that the purified BG-PEG24-Ce6 had the same mass as 
the theoretical mass calculated for coupled Ce6 and BG-PEG24-NH2 (Figure 15). 
 
3.1.2.2 Protein labeling with BG-modified fluorophores and Ce6 
BG-modified Ce6 was conjugated to fusion proteins by incubating them for 2 h at room 
temperature. Protein labeling efficiency was determined photometrically which revealed 82%.    
The photosensitizer reacted solely with the active SNAP-tag and the reaction irreversibly 
blocked with bromothenylpteridine (BTP), as shown by post-incubation with a 1.5-fold molar 
excess of BG-Vista Green. Analysis with the CRi Maestro imaging system showed no 
fluorescence associated with the previously blocked fusion protein (Figure 16). 
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Figure 14: Schematic demonstration of Ce6 modification steps. The photosensitizer Ce6 (Ce6) (1) was modified 
with BG molecule using EDC (2), sulfo-NHS (3) and BG-PEG24-NH2 linker (4) to produce BG-modified Ce6 
(5).  
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Figure 15: HPLC purification profile of BG-PEG24-Ce6.  The Ce6 (A), BG-PEG24-NH2 (B) and BG-PEG24-
Ce6 (C) were purified by reverse phase chromatography using a 2.5µm (4.6 x 50 mm) Water XBridgeTM OSTC18 
column and a flow rate of 1 mL/min.  Monitoring occurred at wavelength of 260 (red curve) and 280 nm (blue 
curve).  
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Figure 16: Analysis of Ce6 photosensitizer by mass spectrometry before and after modification with 
benzylguanine (BG). ESI mass spectrum of Ce6, BG-PEG24-NH2, and BG-PEG24-Ce6. The top panel represents 
Ce6 (597.215 Da), the middle panel represents BG-PEG24-NH2 (1398.761 Da) and the bottom panel represents 
BG-PEG24-Ce6 (1979.004 Da), indicated by asterisks. The diagram presents the relative frequency (%) on the 
y-axis in correlation to the mass-to-charge (m/z) ratio on the x-axis [54].  
 
3.1.2.3 Binding activity of scFv-SNAP-Ce6 to the target cell surface 
To determine the binding activity of scFv-SNAP fusion proteins, flow cytometry analysis was 
carried out using proteins that had been labeled with either BG-Vista Green or BG-Ce6. The 
scFv-425-CAT-AD-SNAP labeled protein showed a strong fluorescence signal on the 
corresponding target cell line (A431, MDA-MB-468, MDA-MB-231 and SiHa) but not on 
control cells (L540 and CHO-K1) after an incubation of 30 min on ice (Figure 17). As 
expected, labeled scFv-Ki4-SNAP showed a strong fluorescence signal on L540 but not on 
A431 and CHO-K1 cells  
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Figure 17: Recombinant protein labeling with BG-modified fluorophores and Ce6. (A) Coomassie brilliant blue-
stained SDS-PAGE with BG-PEG24-Ce6 or BG-Vista Green coupled to scFv-425-CAT-AD-SNAP, and (B) 
corresponding in-gel fluorescence visualization of the fusion proteins. The different dye spectra were unmixed 
based on their spectral patterns using CRi Maestro multispectral imaging system. M, Prestained Protein Marker, 
Broad Range (7-175 kDa); (1) scFv-425-CAT-AD-SNAP incubated with a 1.5-fold molar excess of BG-Vista 
Green; (2) scFv-425-CAT-AD-SNAP which is previously blocked with bromothenylpteridine (BTP), then 
incubated with 1.5-fold molar excess of BG-Ce6 for 2 hr flowed by incubation with 1.5-fold molar excess of 
BG-Vista Green; (3) scFv-425-CAT-AD-SNAP first incubated with a 1.5-fold molar excess of BG-Ce6, and 
then incubated with a 1.5-fold molar excess of BG-Vista Green [54]. 
 
3.1.2.4 Internalizing of scFv-425-CAT-AD-SNAP-Ce6  
Confocal microscopy analysis was used to determine the binding and internalization activity 
of scFv-425-CAT-AD-SNAP fusion protein that had been labeled with BG-Ce6. Confocal 
microscopy revealed strong, specific and homogeneous membrane staining on A431, MDA-
MB468, MDA-MB-231 and SiHa cells incubated with scFv-425-CAT-AD-SNAP-Ce6 
(Figure 18). The labeled fusion protein was specifically and efficiently taken up into EGFR+ 
cell lines after an incubation of 30 min at 37°C but not at 4°C.  In contrast, no signal was 
detected when the EGFR– cell lines L540 and CHO-K1 were incubated with scFv-425-SNAP-
CAT-AD-Ce6 under the same conditions.   
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Figure 18: Binding activity of scFv-425-CAT-AD-SNAP labeled with Vista Green or Ce6 to several EGFR+ cell 
lines. Flow cytometry analysis was carried out after incubating 4 x 105 cells (filled gray curves) with each fusion 
protein for 30 min at 4°C in PBS. Specific binding of (A) scFv-425-CAT-AD-SNAP-Vista Green (light gray 
curves) and (B) scFv-425-CAT-AD-SNAP-Ce6 (light gray curves) to A431, MDA-MB-468, MDA-MB-231, 
SiHa, L540, and CHO-K1 cells were evaluated in parallel. As a control, scFv-Ki4-SNAP labeled with Vista 
Green (A) or Ce6 (B) (black curves) was tested against, L540 CHO-K1 and A431 cells [54].  
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Figure 19: Binding and internalization of scFv-425-CAT-AD-SNAP-Ce6 analyzed by confocal microscopy. 
Confocal images were obtained for the EGFR+ cell lines A431, MDA-MB-468, MDA-MB-231 and SiHa, and 
for the EGFR– cell lines L540 and CHO-K1. All cells were incubated with 0.5 µg scFv-425-CAT-AD-SNAP-
Ce6 for 30 min at 4°C (upper panel) or 37°C (lower panel). (1) Ce6 fluorescence signal; (2) transmitted light; (3) 
overlay of fluorescence signal and transmitted light. Magnification is indicated using the white scale bars [54].  
 
3.1.2.5 Photocytotoxicity of scFv-425-SNAP-Ce6 
The cytotoxic effects of scFv-425-CAT-AD-SNAP-Ce6, scFv-425-SNAP-Ce6 and 
unconjugated BG-Ce6 were evaluated using an XTT-based colorimetric cell proliferation 
assay using four EGFR+ cell lines and CHO-K1 as a negative control. After an incubation of 
24 h after light activation, the viability of A431, MDA-MB-468, MDA-MB-231 and SiHa 
cells treated with scFv-425-CAT-AD-SNAP-Ce6 was reduced significantly in a 
concentration-dependent manner. The IC50 values were 48 nM (A431), 38 nM (MDA-MB-
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468), 200 nM (MDA-MB-231), 218 nM (SiHa) and 45 nM (A431 treated with scFv-425-
SNAP-Ce6). CHO-K1 cells remained unaffected even when exposed to 800 nM of the 
conjugated fusion proteins, and the control construct scFv-Ki4-SNAP-Ce6 had a negligible 
effect on both A431 and CHO-K1 cells (Figure 19A). In contrast, unconjugated Ce6 was toxic 
towards all cell lines with IC50 values of 16 nM (A431), 22 nM (MDA-MB-468), 22 nM 
(MDA-MB-231), 26 nM (SiHa) and 18 nM (CHO-K1). These data are shown in (Figure 19C).  
Both conjugated and unconjugated forms of Ce6 were toxic only after light activation, as 
confirmed by parallel experiments without light activation. No significant reduction in 
viability was observed in any of the cell lines (Figure 19B, D).   
To determine whether scFv-425-CAT-AD-SNAP-Ce6 selectively induced programmed cell 
death in target cells by triggering the apoptotic pathway, we analyzed the activity of caspase-3 
and caspase-7 in A431, MDA-MB468, MDA-MB-231, SiHa and CHO-K1 cells 24 h after 
light activation. Both scFv-425-CAT-AD-SNAP-Ce6 (200 nM) and unconjugated Ce6 (50 
nM) increased the levels of caspase-3 and caspase-7, whereas no significant increase was 
observed in A431 cells treated with 200 nM scFv-Ki4-SNAP-Ce6 (Figure 19E). 
The production of ROS in photoactivated A431 cells was investigated by measuring the 
485/535-nm fluorescence of DCF, produced by the oxidation and deacetylation of 6-carboxy-
2’,7’-dichlorodihydrofluoresceindiacetatedi(acetoxymethyl)ester (H2DCFDA). It was found 
that a burst of ROS synthesis follows light activation in the presence of 200 nM of the 
conjugated Ce6 and 50 nM of the unconjugated Ce6, but there was only a small increase in 
ROS levels in non-irradiated cells, barely above the background level observed in cells that 
were not treated with the photosensitizer (Figure 19F). 
 
 | 52 
 
 
Figure 20: Evaluation of photodynamic therapeutic efficiency. Cell proliferation and apoptosis assays were 
carried out using the scFv-425-CAT-AD-SNAP-Ce6. The cytotoxicity of scFv-425-CAT-AD-SNAP-Ce6 was 
determined against cell lines A431 (■), MDA-MB-468 (▲), MDA-MB-231 (♦), SiHa (●), A431 treated with 
scFv-425-SNAP-Ce6 (►) and CHO-K1 (▼) using the XTT proliferation assay on (A) irradiated cells and (B) 
non-irradiated cells. The cytotoxicity of scFv-Ki4-SNAP-Ce6 against A431 cells (-X-) was tested as a control. 
The same cells were treated with different concentrations of unconjugated Ce6 and cell viability was analyzed 
with (C) and without (D) light activation. (E) Apoptosis was evaluated using the Apo-ONETM Homogeneous 
Caspase-3/7 Assay, with 50 nM Ce6, 200 nM scFv-425-CAT-AD-SNAP-Ce6 and 200 nM scFv-Ki4-SNAP-Ce6. 
(F) The generation of reactive oxygen species (ROS) due to illumination of photosensitized A431 cells was 
detected using the dichlorofluorescein derivative carboxy-H2DCFDA reagent [54]. 
 
 | 53 
 
3.1.3 Specific delivery of polyglycerol-Doxorubicin dendrimers conjugated to the 
scFv-SNAP recombinant protein against cancer cells  
3.1.3.1 Coupling of SNAP-tag fusion proteins to polyglycerol-doxorubicin conjugates 
In order to deliver polyglycerol-doxorubicin dendrimers specifically to EGFR expressing cells 
branched polyglycerol scaffolds (PG) of approximately 10 kDa MW containing five 
equivalents of Doxorubicin/particle were modified with benzylguanine and conjugated to 
scFv-425-CAT-AD-SNAP recombinant protein. All PG-Doxo particles were synthesized by a 
collaboration partner (Dr. Marcelo Calderon, Institute for Chemistry and Biochemistry, FU-
Berlin).    
The polyglycerol dendrimers were successfully conjugated to the scFv using the SNAP-tag 
technology. The conjugated protein was effectively purified from unconjugated protein and 
the free polyglycerol dendrimers using size exclusion chromatography (Figure 20).  
The coupling was evaluated indirectly by evaluating the unconjugated protein after size 
exclusion chromatography. Calculating the accurate coupling efficiency was not achievable 
because it was not possible to separate the conjugated protein using the SDS-PAGE. therefore 
the coupling was evaluated indirectly by evaluating the unconjugated protein after size 
exclusion chromatography using aida image analyzer software which shows that only 18% of 
total protein was not conjugated to benzylguanin modified dendrimer. 
  
3.1.3.2 Flow cytometry analysis of scFv-SNAP conjugated to polyglycerol dendrimer 
The binding activity of the scFv-425-CAT-AD-SNAP-PG-Doxo-IDCC conjugate was 
confirmed by flow cytometry using A431, MA-MB-468 and Panc-1 cell lines that express 
EGFR and CHO-K1 cell line which is lacking this antigen. Flow cytometry data shows a 
rapid and efficient binding of scFv-425-CAT-AD-SNAP-PG-Doxo-IDCC to EGFR+ target 
cell lines, whereas no significant binding signal was detected against EGFR- cells (CHO-K1) 
(Figure 20). Furthermore, no significant signals were observed when PG-Doxo-IDCC 
particles were incubated with all cell lines at 4°C, whereas internalized signals were detected 
when the cell lines were incubated with the PG-Doxo-IDCC particles at 37°C, which reveal 
unspecific uptake of the PG-Doxo-IDCC particles by treated cells (Figure 21).  
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Figure 21: Purification profile of scFv-425-CAT-AD-SNAP-PG-Doxo-IDCC using size exclusion 
chromatography.  (A) The conjugated protein was purified from unconjugated protein and free PG-dendrimer 
using superdex 75 column. The purification profile was monitored at 280 (blue curve) and 650 nm (red curve). 
(B) ) Coomassie brilliant blue-stained SDS-PAGE with BG-PG-Doxo-IDCC or BG-Vista Green coupled to 
scFv-425-CAT-AD-SNAP, and (C) corresponding in-gel fluorescence visualization of the fusion proteins. The 
different dye spectra were unmixed based on their spectral patterns using CRi Maestro multispectral imaging 
system. M, Prestained Protein Marker, Broad Range (7-175 kDa); (1) scFv-425-CAT-AD-SNAP incubated with 
a 1.5-fold molar excess of BG-Vista Green; (2) scFv-425-CAT-AD-SNAP-PG-Doxo-IDCC before size 
exclusion chromatography; (3) eluted scFv-425-CAT-AD-SNAP-PG-Doxo-IDCC; (4) eluted scFv-425-CAT-
AD-SNAP and (5) eluted PG-Doxo-IDCC. 
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Figure 22: Binding activity of scFv-425-CAT-AD-SNAP-PG-Doxo-IDCC to the target cell lines. Flow 
cytometry analysis was carried out after incubating 4 x 105 cells (filled gray curves) with  scFv-425-CAT-AD-
SNAP fusion protein conjugated to PG-Doxo-IDCC particles (black curve) at 4°C, PG-Doxo-IDCC particles at 
4°C (dotted black curve) and at 37°C (gray curve) for 30 min in PBS.  
 
3.1.3.3 Internalizing of scFv-425-CAT-AD-SNAP-PG-Doxo-ICC  
Confocal microscopy analysis was used to confirm the binding and internalization activity of 
recombinant proteins that had been conjugated to the PG-Doxo-IDCC dendrimer. Confocal 
microscopy shows homogeneous and specific membrane staining on A431, MDA-MB-468 
and Panc-1 cells incubated with scFv-425-CAT-AD-SNAP-PG-Doxo-IDCC (Figure 22A, B, 
C), while no signal was detected against CHO-K1 cells after an incubation of 30 min at 4ºC 
(Figure 22C). The conjugated fusion proteins were specifically and efficiently taken up by 
target cell lines after an incubation of 30 min at 37°C but not at 4°C (Figure 22A, B).  In 
contrast, no signal was detected when A431 and CHO-K1cells were incubated with PG-Doxo-
IDCC particles for 30 min at 4ºC and the PG-Doxo-IDCC particles were unspecifically taken 
up into both the cell lines after an incubation of 30 min at 37°C (Figure 22D, E). 
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3.1.3.4 Cytotoxicity of scFv-425-CAT-AD-SNAP- PG-Doxo conjugates 
The cytotoxic effects of PG-Doxo dendrimers conjugated to scFv-425-CAT-AD-SNAP and 
unconjugated PG-Doxo dendrimers were evaluated using an XTT-based colorimetric cell 
proliferation assay with the EGFR+ cell lines (A431, MDA-MB-468 and Panc-1) and CHO-
K1 cells as a negative control. The viability of A431, MDA-MB-468 and Panc-1 cells upon 
treatment with PG-Doxo-BG particles conjugated with scFv-425-CAT-AD-SNAP fusion 
protein was found to decrease significantly in a concentration-dependent manner after an 
incubation of 48 h at 37°C. The IC50 values were 440 nM (A431), 424 nM (MDA-MB-468) 
and 510 nM (Panc-1) (Figure 23A). CHO-K1 cells remained unaffected even when exposed 
to 1600 nM of the conjugated fusion proteins. In contrast, unconjugated dendrimers and free 
doxorubicin were toxic towards all cell lines. The IC50 values for PG-Doxo dendrimers were 
282 nM (A431), 339 nM (MDA-MB-468), 349 nM (Panc-1) and 866 nM (CHO-K1), whereas 
the IC50 values for free doxorubicin were 261 nM (A431), 290 nM (MDA-MB-468), 293 nM 
(Panc-1) and 644 nM (CHO-K1) (Figure 23B).  
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Figure 23: Confocal microscopy analysis of scFv-425-CAT-AD-SNAP conjugated to PG-Doxo-IDCC-BG 
dendrimers. Confocal images were obtained for the EGFR+ cell lines (A431, MDA-MB-468, Panc-1) and for the 
EGFR– cell line (CHO-K1). A431 (A), MDA-MB-468 (B), Panc-1 (C) and CHO-K1 (D) were incubated with 
0.5 µg scFv-425-CAT-AD-SNAP-PG-Doxo-IDCC, whereas A431 (E) and CHO-K1 (F) cells were incubated 
with PG-Doxo-IDCC dendrimers for 30 min at 4°C or 37°C. (1) IDCC fluorescence signal; (2) transmitted light; 
(3) overlay of fluorescence signal and transmitted light.  
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Figure 24: Cell viability analysis of the PG-Doxo dendrimers conjugated to scFv-425-CAT-AD-SNAP fusion 
protein. The cytotoxicity of conjugated particles (■) unconjugated particles (▲) and free doxorubicin (●) was 
evaluated against (A) A431, (B) MDA-MB-468, (C) Panc-1 and (D) CHO-K1 cells by XTT assay using 
different doxorubicin concentrations (0, 100, 200, 400, 800 and 1600) nM after an incubation of 48 h at 37ºC.  
 
3.2 Aptamer mediated siRNA delivery against cancer  
3.2.1 Design of the aptamer-siRNA construct 
The secondary structure of Apt-αvβ3 RNA (the aptamer binding specifically to αvβ3 integrin) 
was predicted using the MFOLD web server [162]. As shown in Figure 24, adding the siRNA 
sequence to 3' end of Apt-αvβ3 RNA did not affect its predicted secondary structure.  
 
3.2.2 Binding of aptamer-siRNA transcripts to the cell surface 
The expression of αvβ3 integrin on the surface of U-87 MG, SiHa, PC-3 and HEK-293T cells 
was confirmed by staining with a commercially-available monoclonal anti-human αvβ3 
integrin antibody. U-87 MG cells express high levels of αvβ3 integrin and showed the highest 
binding shift, whereas SiHa and PC-3 cells express moderate levels and showed smaller 
shifts, and HEK-293T cells express low levels and showed a minimal shift (Figure 25A).  
The binding efficiency of the aptamer-siRNA transcripts was analyzed by flow cytometry.  
All four cell types were incubated with Apt-αvβ3-siEEF2 conjugated to 
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5-iodoacetamidofluorescein (IAF), and efficient binding to U-87 MG, SiHa and PC-3 cells, 
but not to HEK-293T cells was observed (Figure 25B). 
 
Figure 25: Predicted secondary structure for the aptamer and aptamer-siRNA transcripts. (A) Apt-αvβ3, (B) 
Apt-αvβ3-siEEF2 (C) Apt-αvβ3-siNON. The siEEF2 and siNON portions were added to the 3' end of the 
aptamer and form stable hairpins without affecting aptamer folding. 
 
 
3.2.3 Aptamer-siRNA internalization 
All four cell types were incubated with IAF-labeled Apt-αvβ3-siEEF2 at 4°C for 30 min or at 
37°C for 1 h and internalization of the chimeric RNA was investigated by confocal 
microscopy. This revealed strong, specific and homogeneous membrane staining on U-87 MG 
cells, moderate staining on SiHa cells, weaker but still evident staining on PC-3 cells and no 
staining on HEK-293T cells at 4°C (Figure 26A), whereas at 37°C, comparable levels of 
internal staining could be detected indicating that the transcript had been taken up by U-87 
MG, SiHa and PC-3 cells but not by HEK-293T cells (Figure 26B). 
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Figure 26: Binding activity of IAF-Apt-αvβ3-siEEF2 and monoclonal anti-human integrin αvβ3-phycoerythrin.  
Flow cytometry analysis was performed after incubating 4 x 105 cells with RNA or anti-human integrin αvβ3 
antibody for 30 min at 4°C in binding buffer. (A) The anti-human integrin αvβ3-PE (black) was analyzed against 
U-87 MG, SiHa, PC-3 and HEK-293T cells (filled gray). (B) IAF-Apt-αvβ3-siEEF2 (black) analyzed against U-
87 MG, SiHa, PC-3 and HEK-293T cells (filled gray). 
 
3.2.4 Aptamer-siRNA-mediated cytotoxicity 
The cytotoxic effects of Apt-αvβ3-siEEF2 and siEEF2 RNA against all four cell types were 
evaluated using an XTT-based colorimetric cell proliferation assay, with siNON and Apt-
αvβ3-siNON as negative controls. The viability of U-87 MG, SiHa and PC-3 cells exposed to 
Apt-αvβ3-siEEF2 and siEEF2 for 48 h was reduced significantly in a concentration-dependent 
manner (Figure 26). The IC50 values for siEEF2 were 457 nM (U-87 MG), 549 nM (SiHa), 
660 nM (PC-3) and 691 nM (HEK-293T), whereas those for Apt-αvβ3-siEEF2 were 708 nM 
(U-87 MG), 1621 nM (SiHa) and 1513 nM (PC-3). HEK-293T cells remained unaffected 
even when treated with 2000 nM Apt-αvβ3-siEEF2. No clear toxicity was observed after 
treating the cells with siNON and Apt-αvβ3-siNON (Figure 27).  
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Figure 27: Confocal microscopy of U-87 MG, SiHa, PC-3 and HEK-293T cells. (A) IAF-Apt-αvβ3-siEEF2 was 
incubated with U-87 MG, SiHa, PC-3 and HEK-293T cells for 30 min at 4°C, (B) IAF-Apt-αvβ3-siEEF2 was 
incubated with the cells for 60 min at 37°C. (1) IAF fluorescence signal, (2) nucleus stained with Draq5, (3) 
transmission light picture, (4) overlay of 1-3.  
 
3.2.5  Aptamer-siRNA induces apoptosis 
To determine whether Apt-αvβ3-siEEF2 could induce apoptosis in target cells, the activation of 
caspase-3 and caspase-7 in all four cell types was measured after 48 h of exposure to different 
concentrations of the siRNAs and aptamer-siRNAs discussed above. siEEF2 was found to increase the 
caspase-3 and caspase-7 enzymatic activity in U-87 MG, SiHa, PC-3 and HEK-293T cells, whereas 
Apt-αvβ3-siEEF2 negatively affected the caspase-3 and caspase-7 activity of U-87 MG, SiHa and PC-
3 cells but not HEK-293T cells (Figure 28). Apoptosis was not found to be induced in cells treated 
with siNON or Apt-αvβ3-siNON (Figure 28). 
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Figure 28: Cell viability assay using Apt-αvβ3-siRNA. The cytotoxicity of siEEF2 (■) and Apt-αvβ3-siEEF2 
(♦) was evaluated against (A) U-87 MG, (B) SiHa, (C) PC-3 and (D) HEK-293T cells by XTT assay using 
increasing concentrations (0, 100, 250, 500, 1000, 1500 and 2000 nM) of each RNA. Apt-αvβ3-siNON (●) and 
siNON (▲) were used as negative controls at the same corresponding concentrations.  
 
 
3.2.6 Interferon assay 
One of the most important advantages of RNA-based drugs is their low immunogenicity 
compared to antibodies and other proteins. The immunogenicity of presented construct was 
investigated by analyzing the production of interferon β after treating U-87 MG, SiHa and 
PC-3 cells with aptamer-siRNA transcripts. It was observed that treatment did not increase 
interferon β levels above the background levels observed in untreated cells, indicating that 
under the given experimental conditions the aptamer-siRNA transcripts did not trigger type I 
interferon response (Figure 29). 
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Figure 29: Induction of cell apoptosis by siEEF2 (■) and Apt-αvβ3-siEEF2 (♦) in (A) U-87 MG, (B) SiHa, (C) 
PC-3 and (D) HEK-293T cells using the Apo-ONETM Homogeneous Caspase-3/7 Assay with increasing RNA 
concentrations (0, 100, 250, 500, 1000, 1500 and 2000 nM). Apt-αvβ3-siNON (●) and siNON (▲) were used as 
negative controls at the same concentrations.  
 
 
Figure 30: Interferon β detection assay. U-87 MG, SiHa and PC-3 cells were incubated for 48 h with 2 μM of 
RNA transcripts and the secretion of interferon β into the cell culture supernatant was analyzed using an 
interferon β sandwich ELISA kit (PBL). 
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4 DISCUSSION 
Molecular-targeted tumor therapies have emerged for specifically treating tumor cells and to 
reduce the side effects of conventional tumor therapies such as surgery, radiation and 
chemotherapy. Several types of ligands have been used for molecular-targeted tumor 
therapies such as folic acid, transferrin, hormones, vitamins, peptides, aptamers, monoclonal 
antibodies and their fragments. Amongst these ligands, monoclonal antibodies and their 
fragments play a major role in targeting therapies. More than 25 mAbs and 3 antibody 
fragments have been approved by the FDA for human treatments [110, 115] and several 
therapeutic agents have been conjugated to them in order to improve them therapeutic 
efficacy. Furthermore aptamers have been arose in the last two deceases as a promise 
pharmaceutical agents and used for a verity therapeutic purpose including antiviral [134, 163], 
anti-angiogenesis [136, 137], anti-inflammation [138, 164], anticoagulation [137, 141], and 
anti-proliferation [143, 144]. Recently different cell-internalizing aptamers against wide rang 
of cell receptors have been selected and used for drug delivery such as chemotherapeutic 
agents, photosensitizers and siRNA [31-34, 91].   
The data presented in this work relate to the field of tumor targeted drug delivery, with special 
focus on using single chain antibody and RNA aptamer to deliver therapeutic agents including 
photosensitizer, chemotherapeutic payload and siRNA aganst cancer cells. 
 
4.1 Tumor targeted drug delivery using scFv-SNAP tag fusion protein 
Targeted therapy using antibodies has revolutionized cancer treatment, and several antibodies 
that bind to tumor cell antigens have achieved blockbuster status. Conventional antibody-
based therapeutics depends on three approaches: receptor blockade, antibody-dependent 
cellular cytotoxicity and complement-dependent cytotoxicity. All these mechanisms need 
multiple and high doses of the antibody for effective treatment [165]. The efficacy of 
therapeutic antibodies have been improved by covalently linking them to additional effector 
molecules such as radionuclides [166, 167], photosensitizers [12, 13], chemical [55, 168, 
169]or biological toxins [170, 171] and siRNA [27, 172]. However, there are several 
challenges to develop an effective antibody-base delivery system. The major challenge is the 
conjugation of the antibody to the effector molecule. Generally conjugation is done using 
either amino group in lysine side chains or reduced sulfhydryl group of cysteine residues. 
These methods yield heterogeneous products, comprising a mixture of conjugated antibodies 
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with the effector molecules attached at different sites and a variable number of effectors 
attached to each antibody, resulting in a range of molar ratios and different pharmacokinetic, 
efficacy and safety profiles. [173] 
Cycloaddition reactions can provide a good solution to control protein-therapeutic agent 
conjugation by using bioorthogonal groups to attach therapeutic agent. Unfortunately, most 
studies done in this area rely on using heterobifunctional cross-linkers, containing 
succinimidyl ester or maleimide, in order to introduce the bioorthogonal functional group. 
This ultimately leads to similar conjugation problems discussed above [43, 174, 175].  
One of the most successful site-specific conjugation approaches involves the fusion of protein 
of interest to reactive tag sequences. These protein tags can specifically react with chemical 
groups and mediate effector molecules conjugation leading to a highly homogenous product. 
For example, the SNAP tag fusion protein reacts specifically with benzylguanine (BG) 
modified molecules, the CLIP tag fusion protein with benzylcytosine (BC) modified 
molecules, the HALO tag fusion protein reacts with chloroalkane modified molecules and 
tetracysteine (TC) tag with biarsentcal compounds like FlAsH or ReAsH [43].    
SNAP tag is a derivative of the O6-alkylguanine-DNA alkyltransferase (AGT) which has the 
ability to conjugate to BG-molecules depending on its folding pattern. AGT is a DNA repair 
protein which scans the DNA for alkyl adducts on guanine and thymine bases and is 
responsible for removing alkyl adducts from the O6 position of guanines and the O4 position 
of thymine.  This reaction leads to deactivation and degradation of the AGT enzyme. This 
process protects the DNA endogenously, reduces mutagenicity and carcinogenicity rate, and 
might be responsible for tumor resistance to DNA alkylating chemotherapeutic agents [45, 
176].  
The use of SNAP tag for conjugating the effector molecules to the protein of interest provide 
several exploitable features like (1) selectivity of the conjugation (reacts only with BG 
molecules), (2) speed of the reaction (1-2 hr. is enough to get  highly efficient conjugation), 
(3) simplicity of the reaction conditions (PBS can be used without adding any activating 
substrates), (4) flexibility of selecting the expression host, (5) availability of a wide range of 
BG-modified molecules, (6) lack of activity against any other cellular substrates and (7) a 
stable 1:1 stichiochemistry product (SNAP tag reacts with only to one BG molecule) [44, 46, 
47].  
In this study, we investigated the use of SNAP-tag technology to provide a unique 
conjugation site on the single chain antibody and to produce a homogeneous conjugate 
preparation. We engineered a construct in which the SNAP tag cassette was genetically fused 
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to the coding sequence of a scFv antibody which binds specifically to EGFR (scFv-425). This 
endows the antibody with a SNAP-tag and therefore allows site-specific conjugation of BG-
modified substrates.  This conjugation method can be applied to any antibody–therapeutic 
agent combination as long as the antibody carries the SNAP-tag and the substrate is modified 
with a BG group. 
 
4.1.1 Production and site-specific labeling of SNAP-tag fusion proteins 
The scFv-SNAP tag fusion proteins were successfully expressed in HEK 293T cells. These 
cells provide a suitable system that allows rapid expression of the fusion proteins with 
relatively high protein yield which is sufficient for most pre-clinical applications [53, 161]. 
The expression vector contains an eGFP gene which is co-expressed with the fusion protein 
using a bicistronic mRNA via an internal ribosomal entry site [177]. Additionally, the vector 
used contains a zeocin resistance gene. Both eGFP and zeocin genes allow monitoring and 
selection of transfected cells.  
All constructs investigated in this work retained both self-labeling activity of the SNAP-tag 
and the binding activity of the single chain antibodies (scFv-425 and scFv-Ki4) as shown by 
SDS-PAGE analysis, flow cytometry and confocal microscopy. Similar results were reported 
previously for scFv-425-SNAP and scFv-Ki4-SNAP [53, 161]. Moreover, the results 
presented here show that inserting cathepsin adapter between scFv-425 and SNAP also 
retained both parental molecules activities. Previous studies have described that using 
cathepsin adapter might increase the cytotoxicity of immunotoxin [61, 66]. Although 
cathepsin adapter in scFv-425-CAT-AD-SNAP fusion protein was found to digest completely 
by cathepsin enzyme in vitro, it was not possible to observe a clear release of SNAP- 
fluorophore in the cytosol (as described in the master thesis of Carolin Goebels, Fraunhofer 
IME, Aachen). This might be a consequence of the microscope's optical resolution in 
combination with the low frequency of translocation into the cytosol.   
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4.1.2 Specific delivery of photosensitizer Ce6 using scFv-SNAP tag fusion 
protein 
Photodynamic therapy (PDT) is a minimally invasive treatment that uses non-toxic 
photosensitizers and harmless visible light in combination with oxygen to produce cytotoxic 
ROS, which kill malignant cells by apoptosis and/or necrosis [15]. Recently, several 
photosensitizers have been approved for human treatment such as, Photofrin (porfimer 
sodium)  which is used against endobronchial tumors, obstructing esophageal and invasive 
endobronchial non-small cell carcinoma; Foscan (meta-tetrahydroxyphenylchlorin) aganist 
head and neck cancers and Metvix (5-aminolevulinic acid) against non-melanoma skin 
cancers [7].  
PDT has several advantages over the other conventional tumor therapies. The effect of the 
non-toxic photosensitizer is confined to the area targeted by harmless light. Additionally, it 
enables repeated cycles of treatment to treat remissions. The systemic toxicity of PDT is also 
very low compared to chemotherapy [16]. One of the main drawbacks of PDT is the 
scattergun effect of activated photosensitizers, which tends to damage healthy nearby tissue as 
well as tumor cells and also lead to skin and eyes photosensitivity which can last 4-6 weeks 
after PDT [9]. 
Many different photosensitizers have been developed, but we chose Ce6 as a model because it 
has been evaluated extensively in PDT studies and also offer advantageous physical and 
chemical properties. Ce6 has an absorption maximum at NIR light excitation wavelength (664 
nm), which is a good compromise between photon efficacy and light tissue penetration [178].  
A maximum absorption at 664 nm allows a deeper light penetration into tissues, which is 
important for clinical use. Also it is possible to deliver NIR light up to several centimeters 
using laser diodes fiber in combination with diffuser tips in order to reach deeper solid tumors 
[179, 180]. Moreover, Ce6 has more than a threefold higher extinction coefficient (4.0 × 105 
M/cm at the absorption maximum of 664 nm) than other photosensitizers such as Photofrin 
(1.2 × 103 M/cm at 630 nm), and about a twofold higher extinction coefficient than Foscan 
(2.2 × 104 M/cm at 652 nm) [181],and thus is more photoactive. The presence of carboxyl 
groups allows further functionalization of Ce6 [42].  
In this study, the carboxyl group of Ce6 was modified successfully with BG group and highly 
pure BG-modified Ce6 was produced (confirmed by HPLC and mass spectrometry). BG-
modified Ce6 was conjugated to the SNAP tag fused to either scFv-CAT-AD-425 or scFv-
425. As a control construct scFv-Ki4-SNAP tag fusion protein, which binds to CD30 and is 
thus irrelevant for the treatment of EGFR+ tumors, was also labeled with BG-Ce6. The 
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conjugation reaction was efficient, allowing the preparation of homogeneous samples of scFv-
425-CAT-AD-SNAP-Ce6, scFv-425-SNAP-Ce6 and scFv-Ki4-SNAP-Ce6. These 
preparations were tested for their ability to specifically kill tumor cells.  
Flow cytometry results revealed  strong and specific binding of scFv-425-CAT-AD-SNAP-
Ce6 to four EGFR+ cell lines (A431, MDA-MB-468, MDA-MB231 and SiHa) but not to 
EGFR- cell lines (A540 and CHO-K1). One of the major problems of the development of 
photoimmunoconjugates is that chemical properties of the photosensitizer (e.g. 
hydrophobicity, number and arrangement of charged groups) might reduce antibody binding 
affinity to target cells [21, 173].  Therefore, the binding activity of scFv-425-CAT-AD-SNAP 
and scFv-Ki4-SNAP conjugated to BG-Ce6 or to BG-Vista Green (commercial BG-modified 
fluorophores) was analyzed using flow cytometry. The results confirmed no decrease in the 
binding affinity of single chain antibodies conjugated to BG-Ce6 as compared to BG-Vista 
Green Ce6.   
Also confocal microscopy revealed strong, specific and homogeneous membrane staining 
when A431, MDA-MB-468, DA-MB231 and SiHa cells were incubated with scFv-425-CAT-
AD-SNAP-Ce6 for 30 min at 4°C. After 30 min incubation at 37°C, scFv-425-CAT-AD-
SNAP-Ce6 was efficiently taken up into all four cell lines (but not into L540 and CHO-K1 
cells) whereas at 4°C, the scFv-425-CAT-AD-SNAP-Ce6 was not internalized into any of the 
EGFR+ cell lines. Furthermore, confocal microscopy results showed that the scFv-425-CAT-
AD-SNAP-Ce6 mainly localizes in the endosomes of target cells. Both, the accumulation of 
Ce6 fluorescence signal in the endosomes and the internalization activity at 37°C confirmed 
that the internalization of scFv-425-CAT-AD-SNAP-Ce6 is an active process and occurs via 
receptor-mediated endocytosis, which is important to prevent nonspecific internalization of 
Ce6.  
The subcellular distribution of photosensitizers is the most important factor for their 
biological efficacy. Photosensitizers generally localize in the mitochondria, golgi apparatus, 
plasma membrane and endoplasmic reticulum, depending on their physical and chemical 
characteristics, leading to optimal phototoxic effect [182]. Several reports described that the 
conjugated antibodies can alter the localization site of the photoimmunoconjugate.  Abu-
Yousif et al., 2012 and Savellano et al., 2003 demonstrated that conjugation of 
benzoporphyrin derivative (BPD, Verteporfin) with monoclonal anti-EGFR antibody 
(Cetuximab) leads to accumulation of antibody-BPD conjugates in the endosomes while the 
free BPD accumulated in the mitochondria, leading to a reduced phototoxic activity of the 
photoimmunoconjugate [183, 184]. In case of Ce6, there is no such effect because the free 
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Ce6 normally localizes in the endosomes and kill the cells through destroying the endosomes 
[185]. So, it is important to consider the localization site of photosensitizer in case another 
photosensitizer would be conjugated to the scFv-SNAP fusion protein.  
The scFv-425-CAT-AD-SNAP-Ce6 and scFv-425-SNAP-Ce6 were also found to selectively 
kill four human tumor-derived EGFR+ cell lines representing epidermal, breast and cervical 
carcinomas (A431, MDA-MB-231, MDA-MB468 and SiHa) after exposure to light. Similar 
effects were described for an anti-EGFR antibody (Cetuximab) randomly conjugated to 
different BPD using amino group in lysine residues. For example, Cetuximab conjugated to 
BPD monoacid ring A in a 1:7 conjugation ratio was found to specifically accumulate in 
highly expressing EGFR cancer cells (OVCAR-5) and to reduce cell viability with about 50% 
using 250 nM of conjugated BPD with 20 J/cm2 light dose [183].  Also conjugating BPD 
verteporfin  to Cetuximab in ratios of 7:1 and 10:1 lead to reduced cell viability of A431 and 
OVCAR-5 cells to 10% and 50% respectively, using 280 nM of conjugated BPD and 20 J/cm2 
light dose [186]. 
Another approach to conjugate a photosensitizer to anti-EGFR antibody is by conjugating 
10kDa polyethylene glycol molecules to the antibody. Using polyethylene glycol enhances 
photoimmunoconjugates solubility and reduces aggregation. This photoimmunoconjugate was 
able to reduce 90% of A431 cell viability using 140 nM of conjugated PBD [184].  
In a different approach, Sn-(IV) chlorin e6 monoethylenediamine [SnCe6(ED)] was 
conjugated to EGF polypeptide using dextran (Dex) with a 4:3:1 conjugation ratio and human 
serum albumin (HSA) with a 3:3:1 conjugation ratio. Conjugation of SnCe6(ED) to EGF 
through dextran was found to reduce the binding affinity of EGF which leads to a very low 
phototoxic effect of this construct, while conjugating the SnCe6(ED) to EGF using human 
serum albumin retained the binding activity of EGF and had a significant phototoxic effect 
with IC50 of 63 nM against breast cancer cells (MDA-MB-468) [187].     
However, in the approaches described above, the loss of photoimmunotoxicity and variation 
in therapeutic efficacy from batch to batch after random photosensitizer conjugation was not 
investigated. These investigations are not important if therapeutic agents are conjugated 
through the SNAP tag technology which ensures a 1:1 stichiochemistry and no such problems 
[44-47, 161].   
No significant increase in photoimmunoconjugate phototoxicity was observed using a 
cathepsin adapter which was inserted between the scFv and SNAP fragments in order to 
facilitate the release of the therapeutic agent from the endosomes. Essentially, there are two 
explanations for this result: (1) treated cells were incubated for only two hours with the 
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photoimmunoconjugate which may be not enough to release the photosensitizer from the 
endosomes; (2) Ce6 is shown to localize in endosomes and kills the cells by destroying the 
endosomes, [185]. Therefore it was not possible to investigate the ability of cathepsin adapter 
to release Ce6. 
Importantly, the phototoxicity of scFv-425-CAT-AD-SNAP-Ce6 was dependent on the 
presence of light and EGFR. Conjugated and unconjugated Ce6 was found to be toxic only 
upon light activation and hence will reduce the side effects of photoimmunotherapy. The 
highest toxicity was found in A431 and MDA-MB468 cells, which express the largest amount 
of the receptor (1–1.3 x 106 receptors/ cell) [188, 189]. The other cells lines used expressed 
lower levels of EGFR (1.3x105 receptors/cell for MDA-MB-231 and 2 x 104–2 x 105 
receptors/cell for SiHa) [188, 190] and thus the toxicity of scFv-425-CAT-AD-SNAP-Ce6 
was concomitantly reduced, although not to the point where the fusion protein would be 
considered therapeutically ineffective. Thus, scFv-425-CAT-AD-SNAP-Ce6 can target a wide 
range of EGFR+ cells, not only those with the highest expression levels. No toxicity was 
observed when EGFR– cells (CHO-K1) were exposed to scFv-425-CAT-AD-SNAP-Ce6. 
Comparable results were obtained by targeting two EGFR expressing cell lines (A431 and 
OVCAR-5) which express different levels of EGFR 1-1.3x106 and 4x105-1x106) respectively 
with photoimmunoconjugate. The toxicity of photoimmunoconjugate against A431 cells was 
five times higher than OVCAR-5 cells [186].  
The phototoxicity of scFv-425-CAT-AD-SNAP-Ce6 and scFv-425-SNAP-Ce6 were about 
two times lower than the free Ce6 in the highly EGFR expressing cell lines (A431 and MDA-
MB-468) and about nine time lower in moderately EGFR expressing cell lines (MDA-MB-
231 and SiHa), although not to the point where the fusion protein would be considered 
therapeutically ineffective. This effect has also been described by several reports [183, 184, 
186]. In case of scFv-425-CAT-AD-SNAP-Ce6 and scFv-425-SNAP-Ce6 only one 
photosensitizer is delivered per EGFR while other photoimmunoconjugates deliver 3, 7 or 10 
photosensitizer per EGFR and thus show 3-7 times phototoxic reduction compared to the free 
photosensitizer molecule. In spite of above difference, our SNAP tag photoimmunoconjugate 
showed a higher phototoxicity than the others. We believe that the major advantage of using 
SNAP tag to conjugate photosensitizer is that SNAP tag helps to retain the binding activity of 
scFv against the target receptor by providing specific conjugation site away from the antibody 
binding site. Additionally, the SNAP tag prevents the chemical and physical effect due to the 
direct labeling of photosensitizer (e.g. hydrophobicity, number and arrangement of charged 
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groups) by serving as a spacer between the scFv and the photosensitizer. Additionally, the 1:1 
coupling ratio of photosensitizer to scFv-SNAP fusion protein prevents self-quenching of 
photosensitizer excited states which is associated with random conjugation strategies.  
Since we incubated our photoimmunoconjugate with the target cells for 2 h, compared to 
longer incubation periods (4-40) h which were described for other photoimmunoconjugates 
[13, 183, 184, 186, 187], it is proposed that the high phototoxic efficacy with a shorter 
incubation time can be an advantage to reduce skin photosensitization side effect.    
Previously, in vivo experiments showed that scFv-425-SNAP accumulates in mouse kidneys 
directly after injection, and is subsequently detected in the bladder, indicating clearance by 
renal filtration. Despite the rapid clearance reported, the accumulation and retention of scFv-
425-SNAP in tumor tissue was evidently sufficient to yield very high tumor to background 
ratio 10 h post-injection. These results suggest possibilities of in vivo studies with our 
construct.   However, to make our photoimmunoconjugates applicable for clinical treatment, 
increasing the phototoxicity should be considered by increasing the number of 
photosensitizers which are conjugated to the scFv-SNAP fusion protein. This can be achieved 
by conjugating photosensitizers to scFv-SNAP fusion protein using a multifunctional linker. 
Cleavable linkers such as acid label linker; disulfide cleavable linker; or cathepsin cleavable 
peptide linker which is specifically cleaved in the endosomes would enable the release of the 
photosensitizer.  
As an alternative approach BG modified nanoscale vehicles can be conjugated to scFv-SNAP 
fusion protein and used to deliver photosensitizer, this system provide an elegant solution to 
solve photosensitizer problems such as low solubility and stability.  
In recent years, several reports have described delivering different photosensitizers using a 
variety of nanoscale vehicles such as dendrimers, copolymer micelles, liposomes, silica 
nanoparticles and gold nanoparticles [191]. In an interesting approach, a silicon 
phthalocyanine (Pc 4) was loaded within biocompatible poly(ethylene glycol)–poly(ɛ-
caprolactone) block co-polymer micelle modified with 12-amino acid EGFR–targeting 
peptides (GE11). The ester link in the PEG-PCL block co-polymer that was used to build the 
micelle is a pH sensitive component and allows for a site-selective drug release. The GE11-
micelles-Pc4 showed acceleration in drug cellular uptake which subsequently enhanced the 
phototoxicity of Pc 4 [192].   
Although there is a large number of BG group modified fluorophores and cross-linkers 
commercially available, in this study the SNAP tag technology was used for the first time to 
conjugate a therapeutic agent, in this case photosensitizer, to scFv antibody and used it to treat 
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cancer cells. This rapid and efficient method produced a homogeneous conjugate with defined 
pharmacokinetic and therapeutic profile. The study also provided the proof of principle that 
SNAP-tag technology can be used to produce targeted photoimmunotherapeutic agents for 
cancer therapy, avoiding the off-target effects that have thus far limited the development of 
PDT. 
 
4.1.3 Specific delivery of polyglycerol-Doxorubicin dendrimers conjugated to the 
scFv-SNAP recombinant protein against cancer cells  
Nanoparticles-based drug delivery systems have been studied throughout the last decades as a 
strategy to increase the therapeutic agent concentration, especially chemotherapeutic agents, 
in malignant tissue. These systems can overcome the conventional free drug delivery 
problems by increasing the drug stability and solubility, decreasing clearance rate and 
reducing systemic side effects. Improved pharmaceutical properties of nanoparticles can be 
achieved by modifying their surface and size. Macrophage activity against nanoparticles can 
be avoided by generating a  hydrophilic surface and the size should be up to 100 nm in order 
to pass the reticuloendothelial system and increase the circulation rate [24, 39].    
Selective accumulation of nanoparticles can be achieved by passively targeting malignant 
tissue using the distinct pathophysiological characteristics of solid tumor vessels and the 
properties of microenvironments surrounding the tumors [22, 24]. Despite the selective 
accumulation of nanoparticles in the tumor tissue via passive delivery strategies, serious side 
effects are associated with these types of therapeutic nanoparticles like low specificity and 
requirement of high treatment doses [39, 193].     
To avoid the limitations discussed above, several approaches have been developed to 
conjugate therapeutic nanoparticles to specific cell receptor antibodies or ligands [193-196]. 
In our study, we investigated the use of SNAP-tag technology to provide a unique conjugation 
site on the scFv antibody, allowing the conjugation with hyperbranched polyglycerol (PG) 
particles that are covalently coupled to doxorubicin (Doxo) using an acid cleavable linker. 
This linker showed  high stability and pH sensitivity and only 5% of doxorubicin were 
released after 24-h incubation at pH 7.4, while maximum release occurred between pH 5.0 
and 6.0 [197]. Also 30 molecules of liner poly(ethyleneglycol) (PEG) were conjugated to the 
dendrimer in order to enhance dendrimers solubility and to reduce their immunogenicity. To 
increase the conjugation efficiency of PG-denedrimer to scFv-SNAP fusion protein two PEG 
per dendrimer were modified with benzylguanine groups. This modification provides 
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benzylguanine molecules in the outer shell which is more accessible for proteins than the 
benzylguanine groups in the dendrimer core [198].  
Furthermore, polyglycerol dendrimers used in this work contained IDCC fluorophores that 
can be detected in NIR wave length, which can be used for detecting the scFv-SNAP-PG 
dendrimer conjugates in both in vitro and in vivo experiments.     
We used scFv-425 that is genetically fused to the SNAP tag fragment, which allows site-
specific conjugation of BG-modified polyglycerol particles. This conjugation strategy can be 
applied to any protein–nanoparticles combination as long as the protein carries the SNAP-tag 
and the nanoparticle is modified with a BG group. 
The conjugation reaction was efficient, allowing the preparation of homogeneous samples of 
scFv-425-CAT-AD-SNAP-PG-Doxo. We then tested these preparations for their ability to 
specifically target and kill tumor.  
Specific delivery of conjugated particles was confirmed using flow cytometry and confocal 
microscopy analysis. The analysis revealed a strong and specific binding of conjugated 
particles to targeted cancer cells, while no significant unspecific binding activity was 
observed for conjugated particles.  
Using confocal microscopy, it was confirmed that our scFv-SNAP-PG particle conjugates 
were able to internalize to target cancer cells specifically at 37ºC revealing that our conjugates 
are internalized via receptor mediated internalization pathway, whereas no significant 
unspecific internalization was detected in the negative control cancer cells. These results 
revealed that conjugating PG-dendrimer with scFv-SNAP fusion protein abolishes nonspecific 
internalization of PG-dendrimer which is important to reduce its accumulation in normal 
tissues.     
Similar effects were described for mAb425 (anti-EGFR) antibody-conjugated PAMAM 
dendrimer which could efficiently bind and internalize to target cell. Results of this study 
have also revealed that it is the number of chelating agents per conjugate and not the 
dendrimers size which reduces immunoreactivity [199].  
Also scFv-425-CAT-AD-SNAP-PG-Doxo was found to selectively kill EGFR+ (A431, MDA-
MB-468 and Panc-1) cell lines in a dose dependent manner after 48-h incubation. The 
cytotoxicity of scFv-425-SNAP-Ce6 was found to be dependent on the presence of EGFR and 
no toxicity was observed when EGFR– cells were incubated with the same conjugate.  
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Toxic effect of PG-Doxo particles and free doxorubicin on target cells was observed to be 
1.5-2 times higher than scFv-425-CAT-AD-SNAP-PG-Doxo conjugate, which is similar to 
the toxicity range described before against human ovarian cancer A2780 cell line [197]. 
Significant in vitro toxicity differences have been reported between unconjugated drug that 
enter the cells via cell diffusion and a drug nanoparticle conjugated with scFv, which is 
internalized by receptor mediated endocytosis pathway [200]. Although the toxicity of scFv-
CAT-AD-SNAP-PG-Doxo was lower compared to unconjugated particles the specificity of 
scFv-CAT-AD-SNAP-PG-Doxo was found to be tremendously higher, as no toxic effect was 
observed when the negative cells were treated with the conjugated particles which is very 
important for further in vivo experiments.   
Similar results were described for Cetuximab monoclonal antibody which has been 
conjugated with fifth-generation (G5) polyamidoamine dendrimer containing the cytotoxic 
drug methotrexate (MTX). Although cetuximab-G5-MTX was toxic to target cells, in this 
case rat glioma cell line (F98EGFR), a clear reduction of MTX toxic effect was observed using 
cetuximab-G5-MTX conjugates. The free MTX toxicity was more than 500 fold higher than 
cetuximab-G5-MTX in in vitro toxicity experiment and no toxic effect was observed in vivo 
[201]. In another report PAMAM dendrimer was conjugated with multiple EGF peptides. 
This conjugate bound to and internalized into target cells and induced EGFR phosorylation 
that lead to a 2.5-fold higher stimulation of cell growth comparing to free EGF peptide [202].  
In previous studies, a distinct increase in tolerability and antitumor activity of doxorubicin 
polymer conjugates has been shown compared to the free doxorubicin in vivo [197]. These 
results along with the previous in vivo accumulation results of scFv-425-SNAP [53] suggest 
possible exploration of our scFv-PG-Doxo particles for future in vivo studies.      
This study provides the proof of principle that SNAP-tag technology can be used to conjugate 
nanoparticles to single chain antibody and hence to target cancer cells. The SNAP tag 
technology provides an easy, fast and site-specific protein modification which can be used to 
conjugate any type of therapeutic nanoparticles to antibody-SNAP fusion proteins. Since a lot 
of cancer specific antibodies are currently available, this approach seems promising for future 
development and use.      
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4.2 Aptamer mediated siRNA delivery against cancer  
RNAi is an essential process in eukaryotic cells which offer the capability to degrade specific 
target mRNAs in sequence-specific manner. siRNA play a fundamental role in this process by 
targeting their complementary mRNA sequence. In this regard two approaches can be used to 
trigger mRNAs degradation, short hairpin RNA (shRNA) and siRNA. Whereas shRNA need 
to be processed by Dicer enzyme to generate siRNA which then can be incorporated into 
RNA-induced silencing complex (RISC), the use of synthetic siRNA can avoid the Dicer 
process, directly incorporates into RISC and guides the mRNA degradation.   
The potent ability of siRNAs to degrade specific target mRNAs and therefore inhibit gene 
expression makes therapeutic siRNAs promising candidates for the treatment of cancer [172, 
203, 204]. However, inefficient systemic delivery of siRNA to target cells is one of the 
greatest challenges preventing RNAi-based cancer therapy from a breakthrough in the clinic. 
Among several approaches developed to address this issue, the use of aptamers as a targeting 
moiety seems the most practical because aptamer-siRNA transcripts can be easily and 
inexpensive synthesized and they show a low immunogenicity [205-209].  The delivery of 
siRNAs to tumor cells has been achieved using aptamers, but till now all reports have 
described the use of PSMA-specific aptamers that target prostate cancer cells [88, 90, 95-97, 
100]. In this study anti-αvβ3 integrin has been use to deliver siRNA against three human 
tumor-derived cell lines representing brain, cervical and prostate carcinomas (U-87 MG, SiHa 
and PC-3).     
Many integrins are highly expressed in tumor cells [86-90], αvβ3 integrin is a member of 
integrin family, which has been extensively studied. This integrin is expressed in several types 
of tumor cells like prostate, cervical and brain tumors [33, 88, 91]. Several studies have 
proved that a number of integrins are internalized into the endosomal compartments and then 
recycled back to the plasma membrane before they get degraded in the endosomal 
compartments [92-94].     
Like other integrins, αvβ3 integrin is rapidly recycled via endocytotic processesa recycling 
rate of 30 min [94-96]. The high expression of αvβ3 integrin in cancer cells and the efficient 
and rapid recycling via endocytotic processes are important characteristics, which make it a 
good target for therapeutic agent delivery.   
We have extended the principle of previous studies to other types of cancer by using Apt-
αvβ3, an aptamer recognizing αvβ3 integrin, to deliver siEEF2, a siRNA that targets 
eukaryotic elongation factor 2 [209], in order to target U-87 MG, SiHa and PC-3 cells. We 
generated a chimeric RNA molecule by combining siEEF2 and Apt-αvβ3, the latter shown in 
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an earlier report to bind specifically to αvβ3 integrin expressed on the surface of human 
umbilical vein endothelial cells (HUVECs) [86].  
Tumor-specific siRNA delivery is critical when the siRNA targets a serious cellular 
component such as EEF2 because non-specific delivery would destroy the healthy cells also. 
αvβ3 integrin is overexpressed on angiogenic endothelial cells but not on normal cells, and 
the molecule is internalized when activated by its ligand [92]. These properties make the αvβ3 
integrin a promising target for the specific delivery of therapeutic agents.   
The investigation of secondary structure of the aptamer-siRNA chimera shown that the 
presence of the siRNA dose not affected the secondary structure of the aptamer. This was also 
confirmed by flow cytometry results which show that Apt-αvβ3- siEEF2 was sufficient to 
target αvβ3 integrin in all three αvβ3 integrin expressing tumor cell types but not to HEK 
293T cells, which express minimal levels of αvβ3 integrin. Similar results were described for 
anti-PSMA RNA aptamer which has appended with siRNA sequence against elongation 
factor 2 gene without effecting the secondary structure of anti-PSMA aptamer [34]. 
Confocal microscopy revealed strong, specific and homogeneous membrane staining when 
U-87 MG, SiHa and PC-3 cells were incubated with IAF-labeled Apt-αvβ3-EEF2. After 1 h at 
37°C, the IAF-Apt-αvβ3-EEF2 was efficiently taken up into all three cell lines (but not into 
HEK 293T cells) whereas the chimeric RNA was not taken up into any of the four cell types 
after 1 h at 4°C.  This demonstrated that the uptake of Apt-αvβ3-EEF2 is an active and 
specific process and occurred via receptor mediated endocytosis. 
The therapeutic effect of Apt-αvβ3-siEEF2 is dependent on its specific delivery to tumor cells 
by Apt-αvβ3, and the cytotoxic effect of siEEF2, which is based on the induction of 
apoptosis. A control construct combining Apt-αvβ3 with a nonspecific siRNA (Apt-αvβ3-
siNON) showed no effect on the viability of tumor cells and proved that siRNA was the 
effector molecule for toxicity. Also, negligible effect of Apt-αvβ3-siEEF2 on the viability of 
HEK 293T cells, which express minimal amounts of αvβ3 integrin confirmed specificity of 
aptamer-based targeting. In this context, we observed that the overall toxicity of the construct 
depended on the quantity of cell surface receptors. Apt-αvβ3-siEEF2 showed twice the 
toxicity towards U-87 MG cells compared to SiHa and PC-3 cells, reflecting the relative 
higher abundance of αvβ3 integrin on the surface of U-87 MG cells. The relationship between 
receptor density and cytotoxicity increases the therapeutic potential of this chimeric RNA by 
building in a failsafe to prevent the targeting of healthy cells with low levels of αvβ3 integrin. 
The high aptamer-siRNA chimera concentration requirement for in vitro gene knockdown 
compared to previous studies [87, 90, 95] can be due the differences in the target receptors, 
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the internalization pathway of the target receptors, the expression level of the target receptors 
and the targeted cell types. The silencing efficiency can be increased by certain modifications 
in the aptamer-siRNA chimera, these modification can include (1) developing bivalent 
aptamer-siRNA which has been reported to increase the silencing efficiency and the toxicity 
with about 50% comparing to the monovalent aptamer-siRNA chimera [93], (2) truncating the 
aptamer which reduces the total length of the aptamer-siRNA chimera and lead to efficient 
RNA synthesis, (3) swapping the position of the siRNA strands which might lead to increase 
the siRNA guided siRNA strand loading into the RISC and (4) adding a polyethylene glycol 
to the 3'-end of the siRNA sequence to increase the aptamer-siRNA chimera half-life and 
reduce the dose required to inhibit  tumor growth.  
Generally free RNA construct has a small size which is rapidly cleared from the body through 
kidney filtration [210], moreover by systemic treatment RNA expose to endogenous nucleases 
which ultimately lead to degrade free RNA [211]. Thus, nanoscale carriers with a 
hydrodynamic diameter larger than 10 nm provide a promising solution for these problems by 
avoiding rapid clearance from the body. Furthermore nanoparticles can also prevent RNA 
from enzymatic degradation. More importantly, nanoparticles can provide an ideal system for 
escaping the endosome by exploit specific endosomal properties such as the acidic 
environment of the endosomes [58, 212].  
In recent years, several reports have described delivering siRNA against cancer cells  using  
variant types of nanoscale vehicles such as dendrimers [58, 212-215], copolymer micelles 
[216, 217], liposomes [218-220], and gold nanoparticles [150, 221].  
Polyglycerol-based dendrimers have been recently used for siRNA delivery due to advantages 
in increasing siRNA stability, intracellular uptake and subsequently its gene silencing activity. 
Furthermore, siRNA can be released from the dendrimers by exposing to acidic environments 
which provide a good strategy to facilitate releasing of siRNA from the endosomes [119, 
222]. In a previous report, a polyglycerol-based dendrimer has been used to deliver siRNA to 
tumors in vivo. This dendrimer-siRNA complex induced significant gene silencing in vivo 
within 24 h which was associated with a very low level of toxicity in the treated animals 
[213].  
Our collaboration partner Dr. Marcelo Calderon, Institute for Chemistry and Biochemistry, 
FU-Berlin) has provided us with a similar polyglycerol-based dendrimer modified with 
benzylguanine for conjugation with scFv-SNAP tag in order to deliver siRNA. The next step 
will be conjugating these dendrimers with anti-αvβ3 RNA aptamer to deliver siRNA against 
elongation factor 2.  
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In conclusion, we have demonstrated for the first time that an aptamer specifically binding to 
αvβ3 integrin can be used to deliver a cytotoxic siRNA specifically to tumor cells expressing 
αvβ3 integrin. This allows the development of therapeutic modalities composed solely of 
RNA, reducing production costs and potential immunogenicity compared to protein 
therapeutics. The low cost, low immunogenicity and minimal off-target effects achieved by 
the specific targeting of tumor cells suggest that aptamer-siRNA chimeras could represent an 
exciting and efficacious new paradigm for cancer therapy with a significant potential impact 
in the clinic. 
  
 | 79 
 
5 Summary 
Conventional treatments for solid tumors involve removing the malignant tissues by surgery 
followed by chemotherapy and/or radiotherapy. Despite the effectiveness of these therapies, 
the side effects of chemotherapy and radiotherapy are very high because of lack of specificity 
to target malignant cells. Another problem is the development of resistance to these 
treatments by cancer cells 
Targeted drug delivery strategies have been developed to improve therapeutic agents efficacy 
and to reduce non-specific side effects by delivering the therapeutic agents specifically to 
target cells. Several approaches have been investigated to achieve this aim. The differences 
between the cellular compositions of targeted and normal cells have been exploited to develop 
the targeted drug delivery approaches. The differences in cell surface receptors expression 
have widely been used to deliver therapeutic agents by conjugating them with specific ligands 
such as hormones, vitamins, folic acid, peptide, transferrin, aptamers, monoclonal antibodies 
and their fragments. In order to deliver therapeutic agents specifically to cancer cells we have 
conjugated therapeutic agents to a single chain antibody or to an aptamer that bind 
specifically to cancer cell receptors.   
Two types of therapeutic agents were conjugated to the scFv-425 single chain recognizing 
EGFR, the photosensitizer chlorin e6 and the chemotherapy payload polyglycerol-
doxorubicin dendrimer. Standard methods for protein conjugation yield heterogeneous 
products containing a mixture of conjugated antibodies with the effector molecules 
conjugated at different sites and a variable number of effector molecules conjugated to each 
antibody resulting in a range of molar ratios and different pharmacokinetic, efficacy and 
safety profiles. 
To avoid the protein conjugation limitations, we investigated the use of SNAP-tag technology 
to provide a unique conjugation site on the antibody allowing the production of homogeneous 
conjugate preparations. We engineered a construct in which the coding sequence of a scFv 
that binds specifically to EGFR (scFv-425) was genetically fused to the SNAP tag cassette, 
which endows the antibody with a SNAP-tag and therefore allows site-specific conjugation to 
BG-modified substrates.  This conjugation method can be applied to any antibody–therapeutic 
agent combination as long as the antibody carries the SNAP-tag and the substrate is modified 
with a BG group. 
We found that scFv-425-CAT-AD-SNAP conjugated to BG-modified Ce6 can selectively kill 
EGFR+ cells in four human tumor-derived cell lines representing epidermal, breast and 
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cervical carcinomas (A431, MDA-MB-231, MDA-MB468 and SiHa) after exposure to light. 
Also scFv-425-CAT-AD-SNAP conjugated to BG-modified dendritic polymer that loaded 
with doxorubicin molecules kill three human tumor-derived cell lines representing epidermal, 
breast and pancreatic carcinomas (A431, MDA-MB-468 and Panc-1). 
In conclusion, we have demonstrated for the first time the conjugation of therapeutic agents to 
a scFv using SNAP-tag technology. This rapid and efficient method produces a homogeneous 
conjugate with defined pharmacokinetic and therapeutic profiles, and provides proof of 
principle that SNAP-tag technology can be used to conjugate therapeutic agents for cancer 
therapy, avoiding the off-target effects that have thus far limited the development of targeted 
drug delivery. 
In another approach RNA aptamer that binds specifically to cancer cell receptor has been used 
to deliver siRNA against cancer cells. siRNAs silence gene expression by triggering the 
sequence-specific degradation of mRNAs, but the targeted delivery of such reagents remains 
challenging and a significant obstacle to therapeutic applications. One promising approach is 
the use of RNA aptamers that bind to tumor-associated antigens as targeting moieties to 
achieve the delivery of siRNAs to tumor cells bearing specific antigens. RNA-based 
constructs are advantageous because they are inexpensive to synthesize and they have a low 
immunogenicity. We therefore joined an aptamer recognizing αvβ3 integrin to a siRNA that 
targets eukaryotic elongation factor 2 gene, and achieved for the first time the targeted 
delivery of a siRNA to tumor cells expressing αvβ3 integrin causing inhibition of cell 
proliferation and induction of apoptosis in tumor cells.  
In conclusion, we have demonstrated for the first time that an aptamer specifically binding to 
αvβ3 integrin can be used to deliver a cytotoxic siRNA to tumor cells expressing αvβ3 
integrin. This allows the development of therapeutic modalities composed solely of RNA, 
reducing production costs and potential immunogenicity compared to protein therapeutics. 
The low cost, low immunogenicity and minimal off-target effects achieved by the specific 
targeting of tumor cells suggest that aptamer-siRNA chimeras could represent an exciting and 
efficacious new paradigm for cancer therapy with a significant potential impact in the clinic. 
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6 Zusammenfassung 
Die klassischen klinischen Behandlungsverfahren von soliden Tumoren bestehen vor allem 
aus operativen Eingriffen und anschließender Chemotherapie und/oder Bestrahlungen. Diese 
Methoden zeigen zwar ihre Wirksamkeit, aber aufgrund ihrer unspezifischen Wirkung auf die 
Tumorzellen sind sie mit erheblichen Nebenwirkungen verbunden. Außerdem entwickeln 
viele Tumorzellen Resistenzen gegen diese konventionellen Therapien. 
Die Entwicklung von zielgerichteten Drug Delivery Systems führt zu einer Steigerung der 
Effizienz von Therapeutika und der  Reduzierung von nicht-spezifischen Nebenwirkungen. . 
Es existieren verschiedene Ansätze zur Entwicklung von „Drug Delivery systems“. Einer 
basiert auf der Grundlage der unterschiedlichen Rezeptorexpressionsmuster von Krebszellen 
und normalen/gesunden Zellen. Die Unterschiede in der Oberflächenrezeptorexpression 
werden genutzt um zielgerichtet Substanzen durch  Kopplung an spezifische Liganden wie 
Hormone, Vitamine, Folsäure, Peptide, Transferrin, Aptamere und monoklonalen Antikörper, 
anzureichern.  
In dieser Arbeit wurden zwei Wirkstoffe, der Photosensitizer Chlorin e6 und das 
Polyglycerol-Doxorubicin Dendrimer, an das  monoklonale Antikörperfragment scFv-425, 
welches an den EGF-Rezeptor (EGF-R) bindet,  gekoppelt. Die gebräuchlichen 
Proteinkopplungsverfahren führen zu heterogenen Kopplungsprodukten und somit auch zu 
uneinheitlichen Pharmakokinetiken, sowie Effizienz- und Sicherheits-Profilen. Die SNAP-
tagTechnologie jedoch führt zu homogenen KopplungsproduktenDer scFv 425 wurde mit den 
SNAP-Tag fusioniert, dieser ermöglicht die spezifische Konjugation/Kopplung mit BG-
modifizierten Substraten.Die SNAP-Tag Technologie kann für die Herstellung diverser 
Antikörper-abhängiger Therapeutika verwendet werden.  
Mit Hilfe des BG-modifizierten Ce6 gekoppelten scFv-425-CAT-AD-SNAP war es möglich 
vier EGF-R+ Krebszelllinien, Epidermal-, Brust- und Gebärmutterhalskrebs (A431, MDA-
MB-231, MDA-MB468 und SiHa), nach Bestrahlung selektiv abzutöten. 
Außerdem war es mittels eines weiteren Konjugats dem mit Doxorubicin gekoppelten scFv-
425-CAT-AD-SNAP, möglich drei verschiedene Krebszelllinien( (A431 Epidermalkrebs, 
MDA-MB-468 Brustkrebs und Panc-1 Bauchspeicheldrüsenkrebs), abzutöten. 
Am Beispiel des scFv-425 ist es uns erstmalig gelungen,die Möglichkeit eines Einsatzes der 
Kopplung therapeutischer Agenzien an Antikörper mittels SNAP-tag technology in der 
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Krebstherapie darzustellen. Dieses Kopplungsverfahren ermöglicht eine schnelle und 
effiziente Herstellung eines homogenen Kopplungsproduktes mit definierter Pharmakokinetik 
und therapeutischem Profil, ohne unspezifische Nebenwirkungen, welche bisher die gezielte 
Therapieanwendung limitierten.  
Weiterhin wurde ein RNA Aptamer eingesetzt, welches spezifisch an Krebszellen bindet, 
wobei  siRNA   in den Krebszellen angereichert wird. siRNAs führen zu einem 
sequenzspezifischen mRNA Abbau und somitzum sogenannten Silencing der Genexpression. 
Eine zielgerichtete Anreicherung solcher Reagenzien ist kompliziert, was deren 
therapeutischen Einsatz erschwert. RNA basierte Konstrukte bieten hier viele Vorteile, weil 
deren Synthese kostengünstig ist und sie eine geringe Immunogenität besitzen. In dieser 
Arbeit wurde ein Aptamer, welches an αvβ3 Integrin bindet, an die siRNA gebunden, welche 
wiederum das Gen des eukaryotischen Elongationsfaktors 2 bindet. Somit konnten wir 
erstmalig eine zielgerichtete Anreicherung der siRNA an αvβ3 Integrin exprimierende 
Tumorzellen zeigen, welche hierdurch eine Inhibierung der Zellproliferation und Apoptose in 
den Tumorzellen auslösen.  
Zusammenfassend lässt sich sagen, dass wir erstmalig zeigen konnten, dass αvβ3 Integrin 
bindende Aptamere zur zielgerichteten Anreicherung zytotoxischer siRNAs an αvβ3 Integrin 
exprimierende Tumorzellen, verwendet werden können. Dies ermöglicht die Entwicklung von 
neuen Therapieanwendungn welche rein aus RNA bestehen,  im Vergleich zu  
Proteintherapeutika kostengünstiger sind und eine geringere Immunogenität besitzen. All 
diese Eigenschaften der Aptamer-siRNA, die günstigere Produktion, geringere 
Immunogenität und vor allem die spezifische Wirkung, machen sie zu einem 
vielversprechenden Ansatz in der Krebstherapie und könnten letztlich das bisherige 
Behandlungsparadigma zum Positiven verändern.  
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DNA deoxyribonucleic acid  
dNTP deoxynucleotide triphosphate  
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E. coli  Escherichia coli  
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eGFP enhanced green fluorescent protein  
EGF epidermal growth factor  
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et al.  et altera  
FACS fluorescence-activated cell sorting  
M molarity (mol/l)  
mAb monoclonal antibody  
Min minute(s)  
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MW molecular weight  
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Nm nanometer  
Nt nucleotides  
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hAGT  human 0(6) alkylguanine DNA alkyltransferase  
His-tag polyhistidine motif  
IC50 half maximal inhibitory concentration  
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scFv single chain Fv  
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U unit  
UV ultraviolet  
v/v volume per volume  
XTT sodium3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-
nitro)benzenesulfonic acid hydrate  
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